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Background: Measuring functional capacity is an important assessment tool that aids researchers and 
clinicians in determining the diagnosis, prognosis, and management of patients in various 
populations. The gold standard for functional capacity testing is cardiopulmonary exercise testing. 
However, this test requires specialised equipment and trained staff, and is therefore not readily 
available in many clinical settings. The 6-minute walk test (6MWT) is used as a validated alternative, 
requiring minimal resources or training. In 2002 the American Thoracic Society (ATS) published 
guidelines to standardise the implementation of the test. However, considering several constraints, 
especially within the context of ow-resource settings (LRS) researchers and clinicians alike have had 
to adapt the methods used when implementing the test. Using different methods for the same test may 
limit the interpretation and clinical applications of the test. The aim of this theses is to evaluate the 
application and protocols used for the 6-minute walk test within LRS. 
Methods: A scoping review was undertaken to identify published studies that implement adapted 
protocols when conducting the 6MWT. Additionally, the rationale for these adaptations were 
investigated. Five electronic databases were accessed and searched from inception to October 2019. 
Data concerning the study source, participants, reported 6MWT purpose, variations (e.g. course 
length), 6MWT outcome, and rationale for making protocol adaptations were extracted. The findings 
in this study were used to inform the development of a cross-sectional study with the aim to determine 
the agreement between the ATS standard 30m 6MWT pathway, a 10m straight and a 10m figure-of-
eight pathway, in patients with non-communicable disease. 
Results: The search returned 564 records of which 22 studies were included. Studies were 
predominantly conducted in lower-middle income countries. The most common adaptation made to 
ATS guidelines was course length, being either shorter or longer than the standard 30 meters. Few 
studies (n = 8, 36%) provided a rationale for adapting the 6MWT. However, based on these eight 
studies, space limitations was the most common argument for making adaptations. Subsequently, we 
recruited 27 patients with one or more non-communicable disease to perform two 6MWTs. Fifteen 
participants performed both a 30 meter straight and a 10m straight 6MWT and twelve participants 
performed a 30m straight and a 10m figure-of-eight 6MWT. Regardless of chosen configuration (10m 
figure-of-eight versus 10m straight), a shortened 6MWT pathway resulted in a significantly smaller 
6-minute walk distance. Moreover, the difference was larger than the reported minimal clinically 




Conclusion: Strict adherence to the ATS guidelines for conducting the 6MWT is challenging. 
Common adaptations included a change in course length and/or course configuration (chapter 2), with 
such adaptations having clinically relevant implications to the outcome of the 6WMT (chapter 3). 
This provides limitations to the application and interpretation of the test. Researchers and clinicians 
need to take this into consideration when adapting the protocol used for the 6MWT. Reference 
equations that take into account the adaptations should be considered. However, accounting for every 
variation of the test may not be feasible. Alternative tests for functional capacity testing within the 





Agtergrond: Die evaluering van funksionele kapasiteit is 'n belangrike assesseringsinstrument wat 
navorsers en gesondheidswerkers help om die diagnose, prognose en behandeling van pasiënte in 
verskillende populasies te bepaal. Die goue standaard vir funksionele kapasiteitstoetse is 
kardiopulmonale oefentoetsing. Hierdie toets benodig egter gespesialiseerde toerusting en opgeleide 
personeel, en is nie altyd toeganklik in alle kliniese omgewings nie. Die 6-minute staptoets (6MWT) 
word as 'n geldige alternatief gebruik, wat minimale hulpbronne of opleiding benodig. In 2002 het 
die Amerikaanse Torakale Assosiase (ATS) riglyne gepubliseer om die implementering van die toets 
te standaardiseer. In die lig van verskeie beperkings, veral binne die konteks van instellings met lae 
hulpbronne (LRS), moes navorsers en gesondheidswerkers egter die tegniek wat gebruik is tydens 
die implementering van die toets, aanpas. Die gebruik van verskillende tegnieke vir dieselfde toets 
kan die interpretasie en kliniese toepassings van die toets beperk. Die doel van hierdie riglyne is om 
die toepassing en tegniek van die ses minute staptoets binne LRS te evalueer. 
Metode: 'n Omvattende literatuur studie is onderneem om gepubliseerde studies te identifiseer wat 
aangepaste protokolle implementeer tydens die uitvoering van die 6MWT. Die rasionaal van hierdie 
aanpassings was ook ondersoek. Vyf elektroniese databasisse was identifiseer en ondersoek vanaf 
insepsie tot Oktober 2019. Data rakende die studiepopulasie, deelnemers, gerapporteerde 6MWT-
doel, variasies (bv. lengte), 6MWT-uitkoms en rasionaal vir die aanpassing van protokol was 
identifiseer. Die bevindings in hierdie studie is gebruik om die ontwikkeling van 'n dwarsdeursnee-
studie in te lig met die doel om die ooreenstemming tussen die ATS-standaard 30m 6MWT-bane en 
'n 10m-reguit- en 'n 10m-syfer-van-agt-roete te bepaal, by pasiënte met nie -oordraagbare siektes. 
Resultate:  Die soektog het 564 studies identifiseer waarvan 22 studies ingesluit is. Die studies was 
hoofsaaklik in laer- tot middelinkomste lande gedoen. Die algemeenste aanpassing aan die 
Amerikaanse Torakale Assosiasie (ATS) -riglyne was die lengte van die baan, of dit was korter of 
langer as die standaard 30 meter. Minimale studies (n = 8, 36%) verskaf 'n rede vir hierdie aanpassing 
van die 6MWT. Van die agt studies was ruimtebeperkings egter die algemeenste probleem om 
aanpassings te maak. Dus het ons 27 pasiënte met een of meer nie-oordraagbare siektes ingesluit om 
twee 6MWT's uit te voer. Vyftien deelnemers het beide 'n 30 meter reguit en 'n 10 m reguit 6MWT 
uitgevoer en twaalf deelnemers het 'n 30 m reguit en 'n agt figuur van agt 6 MWT uitgevoer. Ongeag 
die aanbeveelde struktuur (10m figuur van agt versus 10m reguit), 'n verkorte 6MWT-baan het gelei 
tot 'n aansienlik kleiner loopafstand van 6 minute. Die verskil was boonop groter as die 
gerapporteerde minimale klinies belangrike verskil. Hierdie bevindinge beklemtoon die kliniese 




Gevolgtrekking: Streng toepassing van die ATS-riglyne vir die uitvoering van die 6MWT is 
uitdagend. Algemene aanpassings het 'n verandering in lengte en/of konfigurasie ingesluit (Hoofstuk 
2), met sodanige aanpassings wat klinies relevante implikasies het vir die uitkoms van die 6WMT 
(Hoofstuk 3). Dit beperk die toepassing en interpretasie van die toets. Navorsers en 
gesondheidswerkers moet dit in ag neem wanneer hulle die tegniek van die 6MWT aanpas. 
Verwysingsvergelykings wat die aanpassings in ag neem, moet oorweeg word. Om elke variasie van 
die toets te bereken, is egter nie moontlik nie. Alternatiewe toetse vir funksionele kapasiteitstoetse 
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Functional capacity, exercise tolerance and cardiorespiratory fitness are considered synonymous 
terms used to describe an individual’s ability to perform activities at both a maximal and submaximal 
intensity.  Functional capacity, traditionally, is quantified by measuring the amount of oxygen 
consumed by an individual using maximum effort in a maximal effort test.(1,2) Additionally, 
functional capacity is also used to describe an individual’s ability to perform everyday activities at a 
sub-maximal level. Functional capacity reflects the health and combined functioning of the 
cardiovascular, pulmonary, and skeletal muscle systems. The assessment of functional capacity 
provides essential diagnostic and prognostic information in various diseases as well as in developing 
appropriate exercise plans for patients in various pathologies.  
Cardiopulmonary Exercise Testing (CPET) is upheld as the gold standard for maximal exercise 
testing. CPET provides information on an integrative response, of the cardiopulmonary system, to 
exercise.(1,3) However, the test requires an advance laboratory setting with specific equipment (e.g., 
ergometer, metabolic cart) and specially trained staff. Additionally, the application of this test is 
limited in patient’s whose performance may be affected by pain, fatigue, impaired balance and/or 
abnormal gait patterns.(4) Ultimately these facets of CPET result in the test not being readily available 
and/or accessible, especially in primary care settings or applicable in all populations. For these 
reasons, the need for an alternative and more accessible field test arose.(1,5) 
The six-minute walk test (6MWT), a sub-maximal field test, was first used in 1982 by researchers 
looking for an alternative to the first time-limited field test. The 12-minute walk test was introduced 
to test the fitness of highly conditioned individuals. Subsequently, they found excellent correlation 
between the distances walked in the 12 and 6 minutes minute limited tests.(1,5,6) In 1984, further 
research of the 6MWT found that using different encouragement strategies during the 6MWT resulted 
in a significant effect on the distances achieved and emphasised a need to standardise the field 
test.(1,7,8) However, it wasn’t until 2002 that the American Thoracic Society (ATS), by way of a 
consensus conference, developed and published guidelines for the standardisation of the 6MWT. The 
aim of these guidelines was to homogenise the clinical application and allow for comparisons 
internationally and across studies.(9,10) 
The ATS guidelines explain details on the practicality of the test, indications for using it, as well as 
factors that may affect the test, amongst others. Moreover, a step by step protocol provides clinicians 
and researchers with safety measures, patient preparation, and guidelines on interpretation. According 





weather, the test can be conducted either indoors or outdoors. The walkway must measure 30m in 
length and be marked at every 3m point. Turnaround points should be marked with a cone, where 
patients are expected to make sharp 180˚ turns.(10) Patients should rest for at least 10 minutes before 
the test, during which safety measures and patient vitals are checked. Furthermore, standardised 
instructions and phrases of encouragement at set intervals are provided.(9)  
The 6MWT is a self-paced, walking test aimed at objectively quantifying functional capacity by 
evaluating the distance a participant is able to walk in 6 minutes.(11–14)  Participant performance is 
interpreted by using this distance (6MWD) as an absolute value comparing different attempts, for 
instance pre- and post-intervention, and as a “percentage of predicted” through the use of previously 
established reference equation.(12) In healthy participants, the 6MWD generally ranges between 400-
700m; with a walking distance less than 82% of predicted considered abnormal.(15,16) Additionally, 
the minimal clinical important difference assists in the interpretation of change in 6MWD between 
several 6MWT attempts. A systematic review by Bohannon et al. established an MCID of 30.5 based 
on six articles in adults with various pathologies.(17) Additional information is obtained from the 
participants rating of dyspnoea and fatigue using the Modified BORG Scale as well as the 
participants’ cardiorespiratory response which is assessed by measuring heart rate and oxygen 
saturation pre- and post- test.(18). The 6MWD thus has several applications: 1) as a once off measure 
to determine functional status, 2) determining the need for and prescription of ambulatory oxygen in 
patients with cardiorespiratory disease and 3) predicting hospitalisation and mortality in patients with 
chronic disease.(19) The 6MWD has several clinical applications, for instance in determining the 
need for and prescription of ambulatory oxygen in patients with cardiorespiratory disease as well as 
predicting hospitalisation or mortality in patients with chronic disease.(19) Within the field of 
rehabilitation science the 6MWT is also used as a measure of efficacy to report on interventions and 
to determine the appropriate exercise prescription in patients with a decreased exercise tolerance. An 
example of such application is the prescription of walking intensity for cardiac rehabilitation at “65%-
75% of the mean speed achieved during a 6MWT”.(11,12)  
Since the development of the ATS guidelines, reference equations for interpreting the 6MWT have 
been established across geographical locations, including various low- and middle-income countries. 
The development of these normative values illustrates the widespread use of the 6MWT as a measure 
of functional capacity and its continued integration in clinical practice. However, despite the apparent 
ease in conducting the test, studies report the use of 6MWT protocols that divert from the widely 
adopted ATS guidelines.(20) Adaptations to the protocols may include changes to the walkway layout 





studies investigated the effect of changing the walkway distance of the 6MWT on the 6MWD in 
patients with COPD. A study by Beekman et al compared the 6MWD achieved on a 30m and 10m 
distance walkway, while a study by Klein et al. compared the 6MWD on a 30m and 20m walkway. 
Both studies conclude that the shorter walkway resulted in participants achieving a clinically relevant 
shorter 6MWD than on the 30m walkway.(22,23) Furthermore, evidence suggests that circular or 
continuous pathways result in longer distances than straight pathways.(24) A systematic review of 
the 6MWT in stroke population reported that of the 127 studies included in their review, the use of 
adapted protocols was more common than ATS guideline compliance. Additionally, they noted that 
both the adherence to the ATS guidelines and reporting of adaptations made to protocols were 
poor.(10) While Brooks et al. reported no significant effect between conducting the 6MWT indoors 
vs outdoors, both settings may have their own limitations. (8,25) While finding a 30m walkway 
indoors may prove difficult, unfavourable weather conditions in may impede outdoor testing. 
However, also in favourable weather conditions and outdoor testing environment may have 
limitations.  For instance, a study into the reproducibility and validity of the use of an outdoor 6MWT 
reported that participants refused to complete the outdoor test; arguably owing to the possibility of 
encountering their neighbours and feeling embarrassed.(26) Moreover, the use of a treadmill 6-minute 
walk test has been studied. While the treadmill eliminates the need for a 30m corridor, the study 
reports that the distance achieved can be 15% lower than the standard test. This method may impact 
the “self-paced” nature of the test.(5) Conducting the 6MWT within the confines of the ATS 
guidelines, although challenging, is important for the standardisation and interpretation of the test. 
These studies highlight the impact of adapting the methods. 
When reviewing the adaptations described in the literature, originating mostly from high-income 
countries, one notices that they pertain mostly to the lay-out (length and configuration) of the 6MWT 
pathway. One can argue that in settings of low resource, where the gold standard (CPET) is 
unavailable (particularly in primary care settings) standardisation of testing is even more crucial. Yet, 
there is reason to believe that there may be additional constraints that (SUPPORT) adaptations to the 
standard protocol. These may include both the access to health care facilities and transport, the lack 
of human resources, (health) illiteracy and others. 
The aim of this thesis is to evaluate the application and methods of the 6MWT in LRS. To that extent, 
in Chapter 2, we conducted a comprehensive scoping review and report on the adaptations which 
have been made to the 6MWT ATS guidelines in LRS as well as the rationale for making these 
adaptations. This scoping review is submitted to the South African Journal of Physiotherapy for their 





6MWT in LRS, the purpose of the adapted test as well as the rationale for the adaptations. The results 
of this review facilitate a platform for discussion around the feasibility of the ATS standardised 
6MWT in these settings. Subsequently, in Chapter 3 we report on a cross-sectional study in 27 
patients with non-communicable disease, in which we investigate the agreement of two modified 
6MWT with a standardised 6MWT in a LRS. In Chapter 4 the results of the scoping review and cross-
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Introduction: The six-minute walk test (6MWT) is a validated tool, of submaximal intensity, used to 
objectively measure functional exercise capacity across numerous pathologies. Individualized 
exercise is a key component of any comprehensive rehabilitation program, in particular for those with 
non-communicable disease associated with poor exercise tolerance. Adequate and individualised 
exercise prescription is linked to improvements in physical function and improvements in quality of 
life. In 2002 the American Thoracic Society (ATS) developed and published guidelines on how to 
implement the 6MWT in a standardised manner. Despite the relative ease of conducting the 6MWT 
as per the ATS guidelines, adaptations such as a change in course length and configuration are being 
implemented, with potential clinical implications Therefore, the objective of this scoping review is to 
identify i) what 6MWT adaptations to the ATS guidelines have been described in low-resource 
settings, ii) the purpose of the adapted 6MWT and iii) the reported argumentation for making these 
adaptations in relation to the specific context. 
Methods: Cochrane Library, EBSCOhost (Africa Wide, CINAHL, Medline), PubMed, Scopus and 
Web of Science were searched from inception until October 2019.  Studies that adapted the 6MWT 
and were conducted in low-resource settings (LRS) were included. Data concerning: the study source, 
participants, reported 6MWT purpose, variations (e.g. course length), 6MWT outcome and rationale 
were extracted. 
Results: The search returned 564 records of which 22 studies were included. Studies were 
predominantly conducted in lower-middle income countries (n=18; 82%). The most common 
adaptation made to the ATS guidelines was course length (n=19; 86%). Eight studies provided a 
rationale for adapting the 6MWT, of which space constraints was the most common.  
Conclusion: Space constraints is the most common reported reason for diverting from the ATS 
guidelines when using the 6MWT in low-resource settings. Heterogeneous adaptations were made to 
the course length, or configuration to address these space limitations. Interestingly, few other 
adaptations were reported (e.g. change of instructions, or alternative safety protocols). The results of 
this review confirm that we need to rethink the value of the ATS guided 6MWT in low-resource 






The six-minute walk test (6MWT) is a validated tool, of submaximal intensity, used to objectively 
measure functional exercise capacity across numerous pathologies including patients with multiple 
co-morbidities.(15,27) This field test is conducted by having a participant walk a fixed lap length 
over a set time period of six minutes (15). In 2002 the American Thoracic Society (ATS) developed 
and published guidelines on how to implement the test in a standardised manner.(9) These guidelines 
aim to promote consistent clinical application of the test thereby allowing comparison, globally, 
across studies.(1)  
The ATS guidelines stipulate that the test is conducted indoors, on a hard-flat surface, using a 30m 
(100ft) straight path (i.e. walkway or lap length); marked with cones on each end. Participants are 
subsequently instructed to walk as far as you can in 6 minutes, and standard phrases of encouragement 
are used at every minute mark. The 6 minute walk distance (6MWD), the primary outcome derived 
from the 6MWT, is calculated by adding the number of completed laps with the distance of the 
unfinished lap the participant was able to achieve by the end of the six minutes.(12) The 6MWD can 
be interpreted by comparing it to a predicted normative value, using previously established reference 
equations or by using it as an absolute value for comparison to a previously completed test by the 
same participant.(28) Subsequently, there are many ways one can use the 6MWD in clinical practice 
or research. 
Individualized exercise is the evidence-based cornerstone of any comprehensive rehabilitation 
program for those with non-communicable disease; in particular those related to lifestyle (e.g. 
diabetes, cardiovascular disease). Improvements in physical function, through exercise, have been 
linked to a reductions in premature mortality and morbidity(29) and clinical risk markers as well as 
improvements in quality of life,(30) amongst others. For instance, patients with COPD have shown 
improvement in quality of life (QOL) and a reduction in their symptoms when following a low to 
mild intensity exercise programme. However, greater physiological responses like increased exercise 
capacity and decreased ventilatory demand are noted when exercise programmes are higher intensity. 
This emphasises the need for patient assessment to help guide clinicians in developing patient 
specific, yet appropriate, exercise programmes.  
While the gold standard for the objective measurement of maximal functional capacity is 
Cardiopulmonary Exercise Testing (CPET),(1) one can argue that this resource-heavy (i.e. 
equipment, training) test is often not feasible or necessary. Conversely, the six-minute walk test 
(6MWT) is often recommended as the field test of choice in day to day clinical practice. Reasons for 





the test is easy to perform, not time consuming, does not require additional equipment or special skills 
and is also more representative of the exertion of everyday activities.(1,12,15) 
However, despite the relative ease of conducting the 6MWT in a standardised way, particularly in 
comparison to CPET, adaptations to “ATS guided 6MWT” are being implemented.(20) Typically, 
these adaptations may include changes to walkway distance and configuration, a practise run or test 
instructions and encouragement etc. The 6MWD may be influenced by these adaptations,(14,21) for 
instance due to changes in gait speed and/or strategy adopted and number of turns made to complete 
the test.(21,31)  
For example, Beekman et al. showed that reducing pathway distance from 30 to 10m, resulted in the 
patients with COPD achieving an average 49.5m shorter distance.(32) The difference in 6MWD 
between the two pathway distances was attributed to the increased number of turns and less time 
spent at optimal walking pace.(32) This discrepancy in 6MWD, in this case due to a difference in 
pathway length, may have clinical impactions. Firstly, if one would compare the 10m results to 
established references equations developed using ATS guidelines, it is likely that the patient’s 
functional abilities will be markedly underestimated. Secondly, the 49.5m is larger than the minimum 
clinically important difference (MCID) reported for the 6MWT in COPD patients of 35m by Puhan 
et al.(33) and 30m by Polkey et al.(34) Thirdly, using data based on different 6MWT protocols 
interchangeably could lead to premature or delayed discharge of patients or inappropriate exercise 
prescription. 
In case of misinformed discharge, this may have a compounding effect, specifically in already 
resource-constrained or overburdened health care environments. Collectively, these examples 
highlight the importance of using standardized testing protocols, particularly in settings of low 
resources, where the gold standard for cardiopulmonary exercise testing is often unavailable and 
physical resources (e.g. space) may be limited. 
The objective of this scoping review is therefore to identify: i) what 6MWT adaptations to the ATS 
guidelines have been described in low-resource settings, ii) the purpose of the adapted 6MWT and 






This scoping review was conducted in accordance with the framework provided by Arksey and 
O’Malley (35) and reported according to the PRISMA guidelines including scoping review 
extensions.(36) 
2.2.1 Data sources and Search Strategy 
Five bibliographical databases were accessed through the Stellenbosch University Library: Cochrane 
Library, EBSCOhost (AfricaWide, CINAHL, Medline), PubMed, Scopus and Web of Science. 
Searches were conducted (BF) from inception to 31 October 2019. Search Terms included variations 
of the following main search terms: six-minute walk test, low-resource setting and developing 
countries (see Addendum A). 
2.2.2 Study Selection 
After the completion of the searches and removing duplicates, titles and abstracts were independently 
screened by two reviewers (BF and MH).  Any disagreements were discussed by the reviewers and a 
third reviewer was consulted (SH) in the case of irreconcilable disagreements. An identical procedure 
was followed for full text screening to determine final full text inclusions. All original research study 
designs that were available in English were considered. Included studies must have reported on and 
used an adapted/modified version of the 6MWT and conducted the test within the context of  low-
resource setting.(37) In the absence of a clear definition for LRS, within the context of an UM or 
HIC, studies were included based on the language (e.g. rural) used by the study in conjunction with 
online resources (detail on the location or context of a specific clinic) and purposeful discussion 
amongst the authors.  After becoming familiar with the sources, decisions were made to exclude case 
studies and case series and any studies that performed the 6MWT according to ATS guidelines or did 
not report on the methods used. Despite searching online resources from inception, articles published 
before 2002 (year of published ATS guidelines) were excluded. 
2.2.3 Data Extraction and Synthesis 
A data extraction form was developed, and revised as necessary, to extract relevant data from the 
included full-text articles and captured under the following headings: source, participants, reported 
6MWT purpose, variations, outcomes and rationale. In case the rationale for making adaptations was 
unclear, corresponding authors were contacted. Data was extracted by the primary reviewer BF and 
verified independently by a second reviewer (MH). In the event of group data (e.g. male and female, 
or intervention/control group) being reported separately, an aggregated 6MWD mean and standard 





excluding data reported separately for diseased groups with healthy controls.(38) In case of 
longitudinal studies only baseline data were extracted. 
2.2.4 Concepts and context 
2.2.4.1 Low-resource setting 
In line with previous research, a low-resource setting was defined as a low-income country (LIC) or 
lower-middle income country (LM) as per the World Bank Criteria,(39) or in the event of an upper 
middle income country (UM) or high income country (HIC) an explicit statement indicating a LRS 
(e.g. rural, minority populations, poverty) was required.(37) 
2.2.4.2 6MWT variations 
The test was considered adapted when it deviated from the 2002 ATS guidelines for the 6MWT, (40)  
and grouped in the following categories:  
 Distance; shorter or longer than 30m (100ft) 
 Configuration i.e. not a straight pathway 
 Venue; not indoors 








See figure 2.1 for the PRISMA flow chart. Of the 564 records identified across the five databases, 
428 remained after removing duplicates. After the initial title and abstract screening 342 articles were 
identified for full text screening. Available full texts were screened for eligibility resulting in the 
exclusion of 320 articles. Reasons for exclusion are provided in figure. A total of 22 studies were 
included in this review.  





Table 2.1 provides an overview of all included studies (n=22). The earliest study included in this 
review was published in 2011 while remaining studies were between 2012 – 2019. Various study 
designs were included with randomised controlled trials (45%) being the most frequent. The most 
common diagnoses in which an adapted 6MWT was reported include respiratory disease (36%) and 
cardiovascular disease (18%). Studies were conducted predominantly in LMICs (n=18; 82%), 
followed by two studies (9%) conducted in LIC (Benin and Malawi), while two (9%) studies were 
conducted in a low-resource context of either an UM (Brazil) or HIC (Australia).  
2.3.1 6MWT Purpose 
The majority of included studies (64%) reported using the 6MWT as a measure of submaximal 
exercise or functional capacity to determine the effect or effectiveness of an intervention in various 
pathologies. Other purposes of the 6MWT included validation of the 6MWT against other 
measures,(16,41) developing normative values,(16,42) or as a descriptive variable in association with 
lung spirometry or QOL.  
2.3.2 6MWT Adaptations 
Figure 2 provides an overview of the adaptations made by the included studies. The most common 
adaptation made to the ATS guidelines was that of course length (n=19; 86%) ranging between 10 to 
85 meters per lap. Of studies that adapted the course length, 10 (53%) reported a shorter pathway and 
9 (47%) reported a pathway distance longer than 30m. Twelve studies reported using a different 
configuration than straight, including using a rectangular (43–46) or square (41) layout. One study 
reported using a 6MWT protocol developed by the study’s investigator.(16) Four studies (18%) 
specifically reported conducting the 6MWT outdoors, 11 (50%) studies conducted the test indoors, 
as per ATS guidelines, while the remaining studies did not report detail on the test venue.  
Instructions as per the ATS Guidelines were used in 7 (32%) of the studies, while 13 (59%) studies 
reported instructions that were modified to include effort (e.g. walk briskly)  or objective (e.g. cover 
as much distance as possible).(42)  
The use of encouragement was generally not well reported, standardized phrases were used (n=3; 
14%), while adapted (n=2; 9%) encouragements included giving time at non-standardized time 
intervals.(41) Some studies refrained from using any encouragement during the test. Three studies 
included in this review reported “other” adaptations which could all be linked to the use of 
technology. Nusdwinuringtyas et al.(16) compared a conventional 6MWT (though 15m course 
length) with one performed on a Biodex® gait trainer, reporting a non-significant mean difference of 





their test. Finally, Worringham et al. reported using Global Positioning System (GPS) monitoring to 
remotely track the distances walked by patients in a natural environment over the course of 6 minutes. 
(48) 
 
Figure 2.2: A graphical summary of the 6MWT Variations for included studies (n=22). 
 
2.3.3 Rationale for making adaptations 
Eight of the included studies, five of which through author correspondence, provided a specific 
rationale for using an adapted 6MWT relative to a conventional ATS guideline version. Space 
constraints, as a result of environmental conditions, was the most common rationale for adapting the 
6MWT.(16,41,43,44,49,50) Worringham et al. reported conducting the test off-site for participants 
unable to attend standard rehabilitation sessions while, Mohammed et al. reported using a treadmill 

















Table 2.1: Overview of included studies 
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Key: m= meters, NA= Not Applicable, NR= Not Reported, * = Low Income Country, † = Low to Middle Income Country, ‡ = Conducted in a Low-resource context of either High/Upper-Middle income country 







To the best of our knowledge this is the first study to explore adaptations to the ATS guidelines 
for conducting a 6MWT, in conjunction with the rationale for making these changes, 
specifically in low-resource settings. Twenty-two studies were identified that predominantly 
reported variations in course length, and configuration. In general, the methods used for 
conducting the 6MWT were poorly reported. 
The 6MWT is recommended as the field test for assessing functional exercise capacity across 
populations. Globally, LRS are seeing a significant, albeit slow, shift in disease burden from 
communicable disease towards non-communicable diseases. Due to the nature of the test its 
applicability to assist in clinical decision making and its’ association with important outcomes 
like hospitalisation and mortality there are compelling arguments for including the 6MWT as 
a key measure across the continuum of care. 
Standardisation in conducting the test is paramount from several perspectives including: the 
construct validity of the test as a measure of functional capacity, the within-patient 
homogeneity moving through various tiers of the health care system, and ability to synthesize 
research outputs across settings for guideline development. This review assists in 
understanding the adaptations to the 6MWT ATS guidelines, drafted in 2002, made in low-
resource settings to inform the academic and clinical landscape and potentially consider the 
need for reconsidering these guidelines in the light of space constraints or other resource 
limitations (e.g. rurality). 
There is a large body of evidence to show that the 6MWD is sensitive to the methods in 
conducting the 6MWT. In this review, space limitations specifically, were most commonly 
reported as a reason for shortening the course length.  Interestingly, almost half of studies 
included in this review reported using a longer course length, though often in combination with 
a course reconfiguration (e.g. 80m, square). While this review demonstrated the adaptations 
made in LRS, it must be noted that high resource settings are challenged with the same 
obstacles when conducting the 6MWT. For instance, Thaweewannakij et al. reported using a 
6x4m rectangular walkway due to absence of a large enough walkway in the communities 
where the tests were conducted.(62) It is also worth noting one specific adaptation to the 
6MWT that we did not consider in the scope of this review. The 2-minute walk test or other 
adaptations to the duration of the test and its potential practical implications (e.g. time savings) 





space. Barriers in service delivery, such as the logistics in accessing care, also need to be 
considered.(63) In this light, the GPS based 6MWT to be used in a real-life environment (48) 
is a particularly interesting technological advancement when moving towards telehealth and 
access to rural populations. A study by Brooks et al. found, within reasonable weather 
conditions, no significant difference in 6MWD between indoor and outdoor 6MWT test 
settings.(25)  
In an academic context, diverting from ATS guidelines might be less problematic in the context 
of pre to post testing when evaluating within patient or sample changes over time. However, in 
clinical settings this may lead to the lack of continuity as referred to earlier. 
2.4.1 Limitations 
This review had some limitations. First, the methods used for conducting the 6MWT, if 
reported, could often only be derived at full-text review stage. For many studies at full-text 
review, it was unclear as to the exact methods used. Given that some of the included studies in 
this review referred to the ATS guidelines as the 6MWT protocol yet still reported adaptations 
thereof, may indicate that adaptations were missed in those studies referring to the ATS 
guidelines with no further detail reported. In addition, the need for many articles to be 
considered at full-text review, led to the selection process being substantially time consuming. 
Second, additional adaptations could have been derived from studies conducted in high-
resource settings not included in this review. Finally, the impact of the adaptations on the 
primary outcome (6MWD) could not be derived from the data due to the underlying 
heterogeneity. Surprisingly, few studies reported validating their adapted 6MWT protocols 
against the gold standard. 
2.4.2 Conclusion 
Space constraints is the most common reported reason for diverting from the ATS guidelines 
when using the 6MWT in low-resource settings. Adaptations were made to the course length, 
or configuration to address these space limitations, often in conjunction. The ATS guidelines 
may need to be revisited, or context-specific norm values need to be developed, in order for 
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Introduction: The 6-minute walk test is a validated tool used to assess functional capacity in a 
range of patient populations. In 2002 the ATS developed a protocol to standardise the 
implementation of the test. However, as a result of space restrictions, adaptations are made to 
the ATS guided protocol in LRS. There is evidence to suggest that adapting the 6MWT 
methods affects the outcome of the test. Affecting the interpretation and clinical application of 
the test. Therefore, the aim of this study was to determine the agreement between the 6MWD 
achieved on the standard 30m, a straight 10m and a figure-of-eight 6MWT. 
Methods: A cross-sectional study was conducted in Bishop Lavis, a socio-economically 
challenged community. Twenty-seven adults with non-communicable disease were 
randomised into performing one of the adapted (straight 10m or figure-of-eight) 6MWT 
pathways in addition to the ATS standard 6MWT on the same day. The order of testing was 
determined randomly. The concordance correlation coefficient was used to assess agreement, 
classified as poor <0.2 as poor, 0.4 - 0.6 as moderate, 0.6 - 0.8 as good and >0.8-1.0 as very 
good. 
Results: Fifteen participants were randomised to Group A, and performed the 10m Straight 
6MWT in addition to the ATS standard 6MWT. The mean (SD) 6MWD30 was 437 (42) 
meters, while the mean 6MWD10 was 371 (57) meters. The mean difference (SE; p-value) 
between the 6MWD was 67 meters (8.6; p < .01) Poor concordance was found between the 
6MWT30 and 6MWT10. Twelve participants were randomised to Group B, and performed a 
6MWTF8 in addition to the 6MWT30. The mean 6MWD30 was 424 (67) meters while the 
mean 6MWDF8 was and 347(58) meters. The mean difference (SE; p-value) between the 
6MWD was 77m (6.0; p < .01) (see figure 3.1). Moderate concordance was found between the 
6MWT30 and 6MWTF8. 
Conclusion:  The present data demonstrates that independent of configuration, hard or soft 
turns, using a shorter pathway reduces the 6MWD. Establishing context specific reference 






The six-minute walk test (6MWT) is a validated field test used to determine functional exercise 
capacity in various population groups, including patients with chronic disease.(11,13) The 6MWT 
measures the distance the participant is able to walk, on a hard flat surface, at their own pace in six 
minutes with the ultimate goal being to walk as far as possible. As per the American Thoracic Society 
(ATS) Guidelines, published in 2002, the participant is allowed to self-pace and stop or rest as 
necessary, walking back and forth, on a 30 meter walkway while standard phrases of encouragement 
are used to motivate the patient.(9) 
In comparison to the 6MWT, exercise capacity can also be measured using other field tests such as 
the incremental shuttle walk test and through cardiopulmonary exercise testing (CPET). The latter is 
still upheld as the gold standard for testing peak exercise tolerance, in particular due to the ability of 
CPET to discern underlying physiological mechanisms leading to exercise intolerance in patient 
populations.(14,64) However, due to the costliness of equipment and specialised training needed to 
perform CPETs, they are less frequently available and used.(14) Additionally, in diseased 
populations, the application of this test may be limited by factors such as pain and fatigue.(4) In 
contrast, the 6MWT is of submaximal intensity and therefore better tolerated, in particular by the 
elderly and specific patient populations.(62,65) Owing to its simplicity, not requiring specific 
exercise equipment or skills, and it’s resemblance to activities of daily living, the 6MWT is therefore 
a widely used field test and proxy of functional exercise capacity.(11,15)  
The primary outcome of the 6MWT is the distance that the participant is able to walk in the six minute 
time frame.(11) The six minute walk distance (6MWD) achieved at the end of the test is of value in 
both clinical and research settings for instance through its association with peak oxygen 
uptake.(13,31) The 6MWT can be interpreted by comparing the 6MWD with a predicted distance 
through the use of relevant reference equations or as an absolute value. The comparison between 
actual and predicted 6MWD informs a clinical interpretation of exercise capacity and facilitates 
prescription of exercise intensity, evaluation of the effectiveness of treatment interventions in 
cardiopulmonary and neurological rehabilitation, and readiness for community reintegration.(11,13)  
In healthy participants a 6MWD ranging between 400 - 700m is considered normal while a distance 
less than 350m is associated with increased mortality risk or viewed as abnormal.(15,28)  
Even with the apparent ease in conducting the test according to the ATS guidelines, and the minimal 
resources required, a scoping review (chapter 2) highlighted that adaptations are made to ATS guided 
protocol for conducting the 6MWTs in low-resource settings. Most prominently, these adaptations 





different components of the test, most commonly walkway length and configuration.(66) However, 
adaptations to the ATS guidelines are not necessarily unique to low-resource settings. A systematic 
review conducted in 2014 comparing time- and distance- limited walking tests reporting on the 
reference values and methods for conducting the 6MWT and found that only 48% of 25 studies used 
a 30m walkway as recommended by the ATS. Again, space limitations was the main reason for using 
a shorter than recommended walkway.(13) While these adaptations may make sense from a pragmatic 
point of view, there are potential clinical implications of doing so. 
Multiple studies have attempted to validate a shorter than 30m course length for the 6MWT, showing 
that using a course length shorter than the ATS recommended 30m, results in a significantly smaller 
6MWD,(31,32) which also exceeds the minimally clinical important difference. Additional research 
emphasises that using a shorter distance has clinical implications for patients, in particular when used 
in conjunction with reference values that are developed based on the ATS standard 30m 6MWT.(32) 
Using the 6MWD achieved on varied pathway lengths can either underestimate or overestimate the 
patient’s abilities affecting patient treatment plans and may lead to unrealistic goals from patient 
interventions.(31–33,67). 
There is reason to believe that the 6MWD achieved, is in part related to the number of turns made 
during the 6MWT as well as the distance walked at an optimal pace. A shorter pathway increases the 
number of turns during the test. Additionally, the minimum distance required, in healthy older adults, 
for acceleration ranges from 2.17 to 3.23m and for deceleration is 1.80 to 1.85m.(23) Consequently, 
a shorter pathway increases the number of turns and the distance available to maintain a steady-state 
phase of walking. This effect may be exacerbated, for instance in those with neurological conditions 
that affect balance and gait patterns and/or strategies.(10) Conversely, studies found that when 
altering the course layout of the 6MWT to continuous pathways (e.g. an oval), resulted in an increased 
or overestimation of 6MWD. Highlighting once more, the effects of modifying pathway 
configuration. As the development of normative values and clinical decision cut-off values for each 
distance is timely and costly, ideally one would try to develop a 6MWT that optimizes space needs 
while retaining the time spent at optimal speed. One such configuration is the figure-of-eight 6MWT, 
which eliminates a “hard turn” and “loss of speed” through the use of a figure-of-eight shaped 
pathway.(20,21) Such a pathway configuration has not been studied in a patient population, and 
specifically in a pragmatic (i.e. non-laboratory) low-resource setting.(66) 
Therefore, the aim of this study was to determine the agreement between the 6MWD achieved on i) 





and 30m straight 6MWT as per ATS guidelines, in an adult population with one or multiple non-
communicable diseases. 
3.2 Methodology 
This cross-sectional study is a sub-analysis of a randomised feasibility trial conducted in Bishop 
Lavis, Cape Town.(17) The protocol for the study has previously been published (trial registration: 
PACTR201807847711940) (Addendum B).(17) Ethical approval for the study was obtained from the 
Stellenbosch University Health Research and Ethics Council (M17/09/031) (Addendum C) as well 
as the Western Cape Department of Health (Addendum D). Data for this study was collected between 
21st January 2019 and 20th December 2019. All data was collected by the same assessor (BF) and 
digitally stored using an online platform (Castor EDC) (Addendum E). All participants were assigned 
a unique identifier when entering the study and data was anonymised prior to the transfer from the 
data collection form to analysis software. Informed consent was obtained at the beginning of the 
larger study in either English or Afrikaans (Addendum F). Additional consent was not required as 
the 6MWT was included as part of physical assessment in the protocol for the larger study. 
3.2.1 Study setting 
Bishop Lavis is a predominantly Afrikaans speaking community,(68) and socio-economic challenged 
community, with ~47% of households living off a monthly income of R3200 or less. The general 
education level in Bishop Lavis can be considered relatively low with only 28% of the population 
older than 20 years having completed grade 12 or higher.(69) The community also battles several 
social issues including drug and alcohol abuse, domestic violence, gangsterism and 
unemployment.(70) Participants for this study were recruited from the Bishop Lavis Community 
Health Centre (BLCHC) a primary health care institution found in the Tygerberg East District of this 
region of the Cape Metropole. Services offered include child health, family planning, the care of 
patients with chronic disease, rehabilitative and dental services.(68) 
3.2.2 Study Population and Sampling 
A convenience sample was drawn from the second follow up phase of the primary study. Adults of 
the Bishop Lavis community who received medical care at the BLCHC with one or more of the 
following NCDs namely cancer, cardiovascular disease, chronic respiratory disease and diabetes 
mellitus were recruited. The inclusion and exclusion criteria for this study were: 
3.2.2.1 Inclusion criteria  
 Adults – 18 years of age or older 





 Confirmed (stable) one or more of the following NCDs – Cardiovascular Disease, chronic 
respiratory disease, cancer, Diabetes mellitus 
 Participant in larger study at final follow-up 
3.2.2.2 Exclusion criteria  
 Pregnant Individual 
 Wheelchair bound 
 General or disease-specific contra-indications for exercise or exercise testing in line with the 
American College of Sports Medicine guidelines 
3.2.3 Sample Size 
The definitive sample size for this study was dependent on the inclusion rate for the larger study, and 
retention of participants at the time of the third and final visit (16 weeks). The adapted 6MWT were 
conducted as part of the physical assessment in the larger study. The sample size of the study was 
limited as a result of COVID-19 countermeasures which required the early termination of the 
overarching study. A sample of 27 participants were included in this study. 
3.2.4 Outcome Measures 
Patient demographic information – age, gender and NCD burden – was recorded at baseline 
assessment. At the 2nd follow up (16 weeks post baseline assessment) physical measures including: 
height (cm), weight (kg) were documented. These measures represent a subset of all measures 
included in the overarching study and were selected due to their reported effect on the 
6MWD.(15)(28)(62)  
3.2.5 6MWT 
Participants, on the same day, performed two different 6MWT configurations. A minimum of 30 
minutes rest between the two 6MWT was implemented. All participants (n = 27) performed a 
standard straight 30m 6MWT (6MWT30) and in addition one of the two adapted pathways. 
Participants were randomised into either Group A or Group B. Group A (n = 15) performed a straight 
10m 6MWT (6MWT10) and Group B (n = 12) performed a 10m figure-of-8 6MWT (6MWTF8) (See 
figure 1). The order in which the two tests were performed as well as group allocation was determined 
randomly using a 1:1 randomization scheme (https://www.randomizer.org/). All participants were 
familiar with the 6MWT having completed 6MWTs at a previous assessment. 
All ATS guidelines, apart from course length and/or configuration, for adapted tests, were adhered 





weather and the availability of physical space as well as how full/busy the indoor passages were. 
Based on previous literature, no impact on the indoor/outdoor settings was expected.(25) Participants 
were instructed to “walk as far as you can” in six minutes and were allowed to stop and rest as needed. 
Assistive devices were used if necessary. Participants were seated for 10 minutes prior to testing in 
which baseline measurements: blood pressure, heart rate, oxygen saturation and fatigue and dyspnoea 
(Modified Borg Scale) were recorded. One lap was demonstrated by the assessor prior to the patient 
starting the test. During testing standardised phrases of encouragement, at one-minute intervals, were 
used. The assessor and a chair were positioned in the middle of the course, with the assessor 
remaining stationary. Laps were counted using a stopwatch. All test measurements (e.g. heart rate) 
were repeated within a minute of completion. Additionally, any other symptoms post testing was 
recorded. When a participant stopped or was unable to continue the test, the distance achieved at that 
time was accepted as the 6MWD and reasons for stopping were documented. All cardiorespiratory 
variables were recorded at that time.  As per the ATS guidelines, participants were monitored 
throughout the assessment for the following: chest pain, ashen appearance, dyspnoea, leg cramps, 
staggering and diaphoresis. No adverse events occurred during testing. All test instructions, 
encouragement and measurement were performed in language of the patient’s choice (English or 
Afrikaans) (Addendum G). 
3.2.6 Statistical Analysis 
Data analysis was performed using statistical software IBM® SPSS® version 26. Data were 
presented as mean (SD) for normally distributed variables and medians for those with non-normal 
distribution. Non-parametric testing was used to test the null hypothesis of no significant difference 
in the 6MWD between: i) a 6MWT30 and 6MWT10 pathway, ii) a 6MWT30 and 6MWTF8 pathway 
and iii) a 6MWT10 and 6MWTF8 pathway. To test the agreement between each of the layouts 
Concordance Correlation Coefficients (CCC) was used. According to McBride and Barnhart et al. 
Lin’s CCC has emerged as the most popular method for measuring agreement between multiple 
methods, on the same subject, measuring the same continuous variable.(71,72) CCC’s measurement 
ranges from 0-1. When all data lie on the 1:1-line perfect agreement is indicated. Altman interprets 
this similarly to Pearson’s correlation coefficient. Agreement was interpreted as follows: <0.2 as 







Patient characteristics are summarised in Table 3.1. Twenty-seven adults with one or more non-
communicable disease were included in this analysis. Participants were between the ages of 31-73 
years old, mostly female (66%), and 17 (63%) patients presenting with more than one co-morbidity. 
All demographic variables were normally distributed, and there were no significant differences 
between these variables across groups. Cardiorespiratory variables measured at baseline and change 
in the measures post 6MWT are reported in Table 3.2. 












3.3.1 6MWT30 vs 6MWT10 
Fifteen participants who were randomised to Group A, performed the 6MWT10 in addition to the 
6MWT30. The 6MWD was normally distributed for the 6MWT30. The mean (SD) 6MWD30 was 
437 (42) meters, while the mean 6MWD10 was 371 (57) meters. All but one participant achieved a 
shorter distance on the 6MWT10. The mean difference (SE; p-value) between the 6MWD was 67 
meters (8.6; p < .01) (see figure 3.1). Poor concordance was found between the 6MWT30 and 
6MWT10 with a r_conc=.40 (95%CI 0.15 to 0.60). (See figure 3.2). There was no significant 
difference between the pre-test cardiorespiratory variables. In addition, no significant difference was 










Diagnosis, n    
 Cardiovascular Disease 13 11 p= 0.681 
 Cancer 1 0 p= 0.362 
 Chronic Respiratory Disease 4 4 p= 0.706 
 Diabetes 9 7 p= 0.930 
More than one co-morbidity, n (%) 
9 (60) 8 (66) p= 0.722 
Sex, n male (%) 
5 (33) 4 (33) p= 0.573 
Age (yrs.), mean (SD) 
59.0 (8.9) 58.8 (10.4) p= 0.896 
Height (cm), mean (SD) 
160 (9.3) 163 (6.4) p= 0.148 
Weight (kg), mean (SD) 
80.8 (14.8) 84.8 (23.9) p= 0.121 
6MWT30= as per the ATS guidelines, a straight walkway measuring 30m in length; 6MWT10= 
straight, shortened walkway measuring 10m in length; 6MWTF8= modified walkway measuring 






Table 3.2: Cardiorespiratory variables 
 
Group A 
(n = 15) 
Group B 





Variables 6MWT30 6MWT10 6MWT30 6MWTF8  MD (SE) 
Distance, m 
 Mean (SD) 
437 (42) 371 (57) 424 (67) 347 (58)  
23(22) 
MD(SE) 67(8.6) 77(6.0)  
Baseline Heart Rate, bpm 
 Mean (SD) 
79 (19) 75 (18) 78 (10) 80 (8)  
4.6(5.6) 
MD(SE) 3.3(5.6) 0.6(2.0)  
Δ Heart Rate, bpm 
 Mean (SD) 
11(16) 15 (14) 9 (16) 8 (13)  
7.0(5.1) 
MD(SE) 3.7(5.3) 0.5(4.4)  
Baseline Dyspnea, Borg 
(0-10) 
 Mean (SD) 
0.1 (0.3) 0.3 (1.3) 0.6 (1.6) 0.2 (0.4)  
0.2(0.4) 
MD(SE) 0.3(0.3) 0.4(0.5)  
Δ Dyspnea, Borg (0-10) 
 Mean (SD) 
1.3 (1.2) 0.7 (1.6) 0.6 (1.6) 1.3 (1.3)  
0.7(0.6) 
MD(SE) 0.7(0.4) 0.8(0.5)  
Baseline Fatigue, Borg 
(0-10)   Mean (SD) 
0.1 (0.5) 0.3 (0.7) 0.2 (0.6) 0 (0)  
NA 
MD(SE) 0.2 (0.2) NA  
Δ Fatigue, Borg (0-10) 
 Mean (SD) 
1.3 (1.5) 1.5 (1.6) 1.7 (1.7) 1 (1.2)  
0.3(0.6) 
MD(SE) 0.1(0.4) 0.4(0.6)  
Baseline SpO2, % 
 Mean (SD) 
94 (3) 95 (3) 94 (3.5) 95 (3)  
0.1(1.2) 
MD(SE) 0.9(1.2) 1.7(1.4)  
Δ SpO2, % 
 Mean (SD) 
1 (2.4) 0.5 (1.6) -1 (3.2) -1 (3.7)  
1.3(1.0) 
MD(SE) 0.5(0.7) 0.2(1.4)  
6MWT= six-minute walk test, MD(SE) = Mean Difference (Standard Error), (SD)= Standard 
Deviation, bpm= beats per minute, SpO2= Transcutaneous Oxygen Saturation, Δ= Change in, NA= 
Analysis not applicable as mean (SD) is = 0 
 
3.3.2 6MWT30 vs 6MWTF8 
Twelve participants who were randomised to Group B, performed a 6MWTF8 in addition to the 
6MWT30. 6MWD data was normally distributed for 6MWTF8. The mean 6MWD30 was 424 (67) 
meters while the mean 6MWDF8 was and 347(58) meters. The mean difference (SE; p-value) 
between the 6MWD was 77m (6.0; p < .01) (see figure 3.1). All participants achieved a shorter 





with a r_conc=.52 with (95% CI -.25 to .0.71. (See figure 3.2) There was no significant difference 
between the pre-test cardiorespiratory variables. In addition, no significant difference was found in 
the change between pre-test and post-test cardiorespiratory variables. 
3.3.3 6MWT10 vs 6MWTF8 
Two groups independently performed a modified 6MWT in addition to the 6MWT30. Fifteen 
participants were randomised to the performing the 6MWT10 vs 12 participants in the group 
performing the 6MWTF8. The mean (SD) 6MWD10 was 371 (57) meters and the mean (SD) 
6MWDF8 was 347(58) meters. The mean difference (SE) between the 6MWD was 23m (22) (see 
figure 3.1) There was a significant difference between the 6MWD of the two modified pathways 
p<0.05. There was no significant difference between the pre-test cardiorespiratory variables between 
groups for the 6MWT10 and 6MWTF8. In addition, no significant difference was found in the change 
between pre-test and post- 
Figure 3.1: 6MWT pathway configuration  
6MWT30= as per the ATS guidelines, a straight walkway measuring 30m in length; 6MWT10= straight, shortened 
walkway measuring 10m in length; 6MWTF8= modified walkway measuring 10m in length; m= meters; MD (SE) = 
mean difference (standard error). All mean differences will statistically significant (p<.05)
Group A (n=15) 
MD (SE)  
67 m (8.6) 
Group B (n=12) 
MD (SE)   
77m (6.0) 
Group A vs Group 
B 









Figure 3.2: Graphical representation of agreement for Group A and Group B. 
This figure illustrates the concordance (agreement) of the 6MWD for Group A between 6MWT30 and 6MWT10 and for Group B between 6MWT30 and 6MWTF8. 
Concordance in Group A is poor while concordance for Group B is moderate. 
6MWT30= as per the ATS guidelines, a straight walkway measuring 30m in length; 6MWT10= straight, shortened walkway measuring 10m in length; 6MWTF8= modified 







The aim of this study was to determine the agreement between the standard 6MWT (according 
to the ATS guidelines) and two alternative pathways. In this study, we showed that a shorter 
distance, independent of whether configured such that it imposed soft (i.e. figure-of-eight) or 
hard turns (10m straight) at each end of the lap, led to a significant shorter 6MWD in a small 
sample of patients with non-communicable disease. This shorter 6MWD had a magnitude 
greater than what has been reported as the minimal clinical important difference (MCID; 
30.5m),(17) and therefore may significantly impact the interpretability of 6MWT findings 
when using such alternative configurations. In fact, there was a significantly greater 6MWD in 
those that walked the 6MWT10 relative to the 6MWTF8 which would indicate that choosing 
to implement soft turns despite a shorter distance, in this population, did not lead to the 
anticipated greater 6MWD. Additionally, there was low to moderate concordance between the 
adapted models and the standard 6MWT30. Both models underestimate the 30m distance, 
however the 6MWTF8 was more consistent in the amount and variance in the underestimation. 
As shown by the greater mean difference yet, moderate concordance between 6MWT30 and 
6MWTF8. 
To our knowledge, one other study used a figure-of-eight configuration to determine its impact 
on walking distance and gait parameters (e.g. stride length) albeit in healthy adults of different 
age groups. Barnett et al. report that the standard 30 m 6MWT resulted in the largest 6MWD 
and highest gait speeds. Second to this is the 10m figure-of-eight 6MWT and 15m 6MWT, 
producing a greater 6MWD than 10m 6MWT, recommending the figure-of-eight 6MWT when 
faced with space limitations. Another element to consider is the effect of course configuration 
on gait variability and the gait strategy adopted by participants. A study investigating gait 
variability in older and younger women found greater gait variability in repeated walking path 
trials vs continuous walking trials with higher SDs in the older (64 ±6.3years) women.(75) The 
results in this study agree with the finding, by Barnett et al., that the 30m straight pathway 
produces the greatest 6MWD. However, as reported using the continuous pathway eliminating 
the hard and frequent turning produced a significantly smaller 6MWD compared to the standard 
30m 6MWT in this study. Additionally, the mean distance achieved on the 10m figure-of-eight 
6MWT was smaller than the mean distance achieved on the 10m straight 6MWT. The findings 
in this study does not support the use of a 10m figure-of-eight 6MWT as a substitute of the 





Interestingly, while the 6MWT is regarded as a field walk test of sub maximal intensity, the 
results in this relatively small sample of patients with NCD showed no significant change in 
any of the measured cardiorespiratory variables (e.g. Heart Rate) regardless of the 6MWT 
layout. One previous study compared the cardiorespiratory response in patients with Type II 
Diabetes Mellitus and matched controls. Both groups walked a similar distance (590(75) vs. 
605(69) m; p = 0.458) and reported similar ratings of perceived exertion (RPE) after the 
6MWT (4.19(1.56) vs. 3.65(1.54); P = 0.147). However, the group with Type II diabetes 
Mellitus, at the end of the 6MWT had a higher heart rate (108(23) vs. 95(18) beats per minute; 
p= 0.048) and systolic blood pressure (169(26) vs. 147(22)mmHg; p= 0.003).(76)While the 
use of modified and alternative pathways (e.g. 6MWTF8) may affect these variables, the 
standard 30m walk test did not produce noticeable changes in cardiorespiratory variables either. 
The reasoning for the reduced response needs to be explored. One such reason may pertain to 
the understanding of the instructions. 
A study investigating the influence of alternate instructions on 6MWD concluded that when 
using phrases such as “walk as fast as you can” instead of the standardised “walk as far as you 
can” results in a larger 6MWD.(77) The ability to make an informed “judgement” as to what 
is required to walk as “far” as you can requires a level of abstract thinking that may be 
jeopardized specifically when growing up or living in a low-resource setting (i.e. lack of 
education). This notion is supported by studies reporting the interaction between 6MWD and 
contextual factors like the level of education and socio-economic status.(28,78) The Bishop 
Lavis community (Cape Town, South Africa) is a structurally marginalised community 
exposed to a variety of aspects one could refer to as being of “low-resource”. These include 
lack of (quality) education, poverty, unemployment, multiple comorbidities, and 
violence.(69,79) Considering these factors, it is plausible to believe that the instructions “walk 
as far as you can” may be ambiguous and subsequently questions the validity of the test, and 
specifically its instructions, to solicit a submaximal measure of functional exercise capacity in 
this setting. Surprisingly, only a few studies (n = 11) have adapted instructions when using the 
6MWT in low-resource settings.(66) However, it was unclear what the rationale was behind 
the specific changes from the literature or author correspondence. Future research may explore 
the impact of socio-economic factors like education on 6MWD, and alternative instructions 






Measuring functional capacity is an important component of managing patients with various 
pathologies and the 6MWT is a widely accepted field test to do so. Its clinical utility, in part, 
depends on the availability of normative values that assist in interpretation and provide a 
guideline for exercise prescription. As most normative values are based on an ATS guided 
6MWT, including a 30-meter lap length, a variety of settings may encounter challenges in using 
the test when such a configuration is unavailable. While the use of the 6MWT continues to 
grow in both clinical and research settings, however, strict adherence to the ATS guidelines is 
not always practical, especially in LRS. Clinicians and researchers alike need to be cognisant 
of the adaptations they make when implementing the 6MWT especially when interpreting the 
test and using it to determine prognosis and inform exercise prescription. Additionally, 
thorough documentation of the protocols used is important especially for the continuum of care 
and for others intending to adopt similar methods for a specific population. 
3.4.1 Limitations 
This study has some limitations. First, as a result of COVID-19 countermeasures we were 
required to terminate the overarching study early, limiting the sample size for this sub study. 
As a consequence, restrictions were implemented as to the complexity of analyses available. It 
would be particularly interesting to explore parameters which may explain the variance in 
6MWD between the 6MWT30 and the modified pathways. A second limitation, albeit also a 
strength, is the heterogeneity in NCD profiles, including multiple co-morbidities, in our 
sample. While this speaks to the pragmatic nature of our enquiry and the settings in which the 
study was performed, it may dilute our ability to infer conclusions for specific medical 
conditions (e.g. stroke). Finally, a third limitation is the lack of spatio-temporal gait parameters 
during the walking test, including time spent at optimal walking pace, stride variability, and 
balance disruptions using hard and/or soft turns. This could provide additional information 
around the gait strategies such as pace on the different configuration and if and how they 
differed. However, one could argue whether such analysis would not require a more controlled 
testing environment than the community-based health centre which was the current testing site.  
3.4.2 Conclusion 
Independent of configuration, requiring hard turns (6MWT10) or soft turns (6MWTF8) using 
a shorter pathway reduces the 6MWD relative to the expected 6MWD of the ATS standard 
6MWT30. The shorter distance found when reducing the space requirement for a 6MWT 
impacts its use in conjunction with established reference values. Furthermore, the lack of 





nature in this population. In light of the burden of chronic disease, establishing 
context/configuration specific reference values, or developing and validating alternative 






The objective of this thesis was to evaluate the application and procedures used when 
conducting the 6MWT in LRS, especially when access to the gold standard of exercise capacity 
testing is inaccessible. Assessing the body’s response to exercise in individuals with various 
diseases is an important tool that assists in diagnosis, prognosis, and informs patient 
management. However, the scarcity of both physical and human resources within LRS as well 
as the constraints experienced by patients and their ability to access care may affect the ability 
to offer standardised forms of testing even for the simpler of field walk tests. 
Given these challenges, amongst others, ensuring that health care professionals are equipped 
with pragmatic yet valid tools to use in clinical practice that can assist clinical decision making 
and monitoring the efficacy of the treatment provided is vital. Being able to assess functional 
capacity, using a pragmatic field test, can be such a tool.  
Therefore, in Chapter 2 we conducted a scoping review to see what adaptations to a 
standardized (ATS guidelines) 6MWT were reported, specifically in settings of low resource. 
Our findings concur with the notion that in particular, space constraints may limit the use of an 
ATS standard 6MWT, as changes were reported in lap length and configuration.  Subsequently, 
in Chapter 3, we tested the agreement of the standard 30m 6MWT and two adapted pathways, 
a straight 10m 6MWT and a 10m figure-of-eight 6MWT. The 6MWT using a figure-of-eight 
configuration was of particular interest due to its potential in alleviating the “loss of distance” 
attributed to a higher number of hard turns and variability in speed with a conventional straight 
10m lap length. The latter has been proposed as the main reason for a loss in 6MWD when 
comparing a straight 10 versus 30m 6MWT. If this hypothesis was true, the 6MWD achieved 
through the 6MWTF8 could be used in conjunction with normative values for the 6MWT 
derived from an ATS standard 6MWT and thereby opening opportunity for the use of the 
6MWT in LRS without the need for developing new normative values. Unfortunately, the 
results described in Chapter 3 disproved that hypothesis. Although the figure-of-eight 6-MWT 
distance showed moderate concordance with the ATS standard 6MWT distance both, 
6MWT10 and 6MWTF8, pathways led to a shorter 6MWD at a magnitude greater than the 
minimally clinical important difference. While this is, to our knowledge, the first report of 
using such a configuration (6MWTF8) in a patient population, these findings concur with a 





Furthermore, the validity of functional capacity testing using the 6MWT (although relatively 
simple) in a LRS may need to be relooked; in particular in relation to the instructions used. The 
basis of this finding is the lack of change in any of the physiological parameters that were 
obtained pre-to-post 6MWT, independent of the configuration. This finding was further 
substantiated by personal experiences in conducting the 6MWT in various populations and the 
perceived lack of comprehension in understanding the 6MWT instructions.  
An alternative way to reduce any space constraints, is using a real-world, GPS based, walking 
test. This would be in line with some of the technological advances that also trickle through to 
historically low-resource settings. However, to our knowledge, no standardization of such a 
GPS-based 6MWT have been proposed yet. Future studies could invest in developing 
normative values or reference equations for more commonly used configuration and lengths, 
including a free-moving GPS based model. Alternatively, other or new field tests, that require 
less physical and/or human resources can be considered and specifically tailored to LRS. 
Stringent adherence to the ATS guidelines for the 6MWT is challenging. Clinicians and 
researchers, when using the 6MWT should be cognisant of the effect that implementing 
adaptations impacts the outcome and potentially, the clinical applications of the test. In absence 
of a pragmatic yet working model for the 6MWT, it may be important to ensure that at a 
minimum, identical formats of the 6MWT across the continuum of care in a specific setting; 
meaning that the same configuration for the 6MWT is used at a tertiary, secondary and primary 
care level in a specific setting and for a specific patient. A revision of the ATS guidelines, 
specific for low-resource settings may assist the field further. Additionally, alternative methods 
for testing functional capacity should be explored. 
4.1 Conclusion 
There is extensive evidence that describes the impact of adapting the methods when conducting 
the 6MWT.(Chapter 1) However, as a result of the constraints experienced by both health care 
providers and those who make use of the services offered, adaptations are implemented 
(Chapter 2). In the absence of access to the gold standard CPET for functional capacity testing, 
in this population, conducting the 6MWT according to the ATS guidelines (30m) results in the 
best performance within each participant (Chapter 3). Additionally, this allows for 
interpretation according to existing reference equations. Within the confines of LRS we need 
to explore the development of reference equations that take into consideration the course length 
as well as the configuration. However, it can be argued that developing a set of reference 





functional capacity testing within the context and confines of LRS needs to be considered and 
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Addendum A: PUBMED Search Strategy 
# Search Terms 
#1 Afghan*” OR “Armenia*” OR “Bangladesh*” OR “Basutoland” OR “Basuto*” OR 
“Benin*” OR “Bhutan*” OR “Bolivia*” OR “Burkina Faso” OR “Burma” OR 
“Burmes*” OR “Burundi*” OR “Cabo Verde*” OR “Cambodia*” OR “Cameroon*” 
OR “Cape Verde*” OR “Central African Republic” OR “Central America*” OR 
“Ceylon” OR “Chad*” OR “Comoro Islands” OR “Comoros” OR “Comorian*” OR 
“Congo*” OR “Cote d'Ivoire” OR “Djibouti*” OR “Egypt*” OR “El Salvador*” OR 
“Eritrea*” OR “Ethiopia*” OR “French Somaliland” OR “Gambia*” OR “Gaza*” OR 
“Georgia”* OR “Ghana*” OR “Gold Coast” OR “Guatemala*” OR “Guinea*” OR 
“Guinea-Bissau*” OR “Haiti*” OR “Honduras” OR “Honduran*” OR “Ifni” OR 
“India*” OR “indigenous” OR “Indonesia*” OR “Ivory Coast” OR “Kenya*” OR 
“Kirghizia*” OR “Kirghiz” OR “Kyrgyz” OR “Kirgizstan*” OR “Kiribati” OR 
“Democratic People's Republic of Korea” OR “North Korea*” OR “Kosovo” OR 
“Kyrgyzstan” OR “Kyrgyz Republic” OR “Lao PDR” OR “Laos” OR “Laotian*” OR 
“Latin America*” OR “Lesotho” OR “Mosotho*” OR “Liberia*” OR “Madagascar” 
OR “Malagasy” OR “Malawi*” OR “Mali*” OR “Mauritania*” OR “Mayotte” OR 
“Melanesia*” OR “Micronesia*” OR “Moldova” OR “Moldovia*” OR “Morocco” OR 
“Moroccan*” OR “Nicaragua*” OR “Niger*” OR “Nigeria*” OR “Nyasaland” OR 
“Pakistan*” OR “Papua New Guinea” OR “Philipines” OR “Filipinas” OR “Filipino*” 
OR “Philippines” OR “Phillipines” OR “Phillippines” OR “Ruanda-Urundi” OR 
“Rwanda*” OR “Samoa*” OR “Sao Tome*” OR “Samoan Islands” OR “Senegal*” 
OR “Sierra Leone” OR “Sri Lanka*” OR “Solomon Islands” OR “Somalia*” OR 
“Sudan*” OR “Swaziland” OR “Swazi*” OR “Syria*” OR “Tadjikistan*” OR 
“Tadzhik*” OR “Tadzhikistan*” OR “Tajikistan*” OR “Tanzania*” OR “Timor-
Leste” OR “Togo*” OR “Togolese Republic” OR “Uganda*” OR “Ukrain*” OR 
“Upper Volta” OR “Urundi” OR “Uzbek*” OR “Uzbekistan” OR “Vanuatu” OR “Ni-
Vanuatu” OR “Viet Nam” OR “Vietnam*” OR “West Bank” OR “Yemen*” OR 
“Zaire” OR “Zambia*” OR “Zimbabwe*” 
#2 (“low-resource setting” OR “resource-constrained setting” OR “resource poor setting” 
OR “resource-poor setting” OR “resource limited setting” OR “resourcelimited setting” 
OR “low-resource settings” OR “resource-constrained settings” OR “resource poor 
settings” OR “resource-poor settings” OR “resource limited settings” OR “resource-
limited settings”) 
#3 (developing countries[MeSH]) AND (developing OR “less* developed” OR “under 
developed” OR underdeveloped OR “middle income” OR “low* income” OR 
underserved OR deprived OR poor* AND countr* OR nation* OR population*) 
#4 #1 or #2 or #3 
#5 “six minute walk test” OR “six-minute walk test” OR “6 minute walk test” OR “6-
minute walk test” OR “6MWT” OR “6-MWT” 
#6 #4 AND #5 
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AbstrACt
Introduction Non-communicable diseases (NCDs) are 
the leading cause of death globally. Even though NCD 
disproportionally affects low-to-middle income countries, 
these countries including South Africa, often have 
limited capacity for the prevention and control of NCDs. 
The standard evidence-based care for the long-term 
management of NCDs includes rehabilitation. However, 
evidence for the effectiveness of rehabilitation for NCDs 
originates predominantly from high-income countries. 
Despite the disproportionate disease burden in low-
resourced settings, and due to the complex context and 
constraints in these settings, the delivery and study of 
evidence-based rehabilitation treatment in a low-resource 
setting is poorly understood. This study aims to test the 
design, methodology and feasibility of a minimalistic, 
patient-centred, rehabilitation programme for patients with 
NCD specifically designed for and conducted in a low-
resource setting.
Methods and analysis Stable patients with cancer, 
cardiovascular disease, chronic respiratory disease and/or 
diabetes mellitus will be recruited over the course of 1 year 
from a provincial day hospital located in an urban, low-
resourced setting (Bishop Lavis, Cape Town, South Africa). 
A postponed information model will be adopted to allocate 
patients to a 6-week, group-based, individualised, patient-
centred rehabilitation programme consisting of multimodal 
exercise, exercise education and health education; or 
usual care (ie, no care). Outcomes include feasibility 
measures, treatment fidelity, functional capacity (eg, 6 min 
walking test), physical activity level, health-related quality 
of life and a patient-perspective economic evaluation. 
Outcomes are assessed by a blinded assessor at baseline, 
postintervention and 8-week follow-up. Mixed-method 
analyses will be conducted to inform future research.
Ethics and dissemination This study has been approved 
by the Health Research and Ethics Council, Stellenbosch 
University (M17/09/031). Information gathered in this 
research will be published in peer-reviewed journals, 
presented at national and international conferences, as 
well as local stakeholders.
trial registration number PACTR201807847711940; 
Pre-results.
IntroduCtIon  
Non-communicable diseases (NCDs) are 
the leading cause of death globally. Almost 
three quarters of NCD-related deaths occur 
in low-income and middle-income coun-
tries (LMICs).1 Moreover, approximately 
60% of NCD deaths occur before the age 
of 70 with 82% of these ‘premature’ deaths 
occurring in LMICs.1 Cardiovascular diseases 
account for most NCD deaths (17.5 million 
annually), followed by cancer (8.2 million), 
respiratory diseases (4 million) and diabetes 
(1.5 million). These four groups of diseases 
account for 82% of all NCD deaths and 
54% of loss in disability-adjusted life years; 
however, they share important commonalities 
in terms of modifiable risk factors.1 
South Africa is facing evolving health-
care needs moving from a predominantly 
communicable disease profile towards a NCD 
profile. This cannot be contributed solely to 
the remarkable improvements concerning 
strengths and limitations of this study
 ► This is the first feasibility study of patient-centred 
rehabilitation for non-communicable disease, spe-
cifically tailored to the context of an urban, low-re-
source setting.
 ► This study uses a postponed information randomis-
ation model to avoid randomising patients to usual 
care.
 ► This study will inform feasibility and cost–benefits 
to upscale rehabilitation for non-communicable dis-
ease in low-resource settings.
 ► The experimental group size is dependent on the pa-
tient’s willingness to participate in the rehabilitation 
programme.
 ► Generalisation of results to other low-resourced set-
tings needs to be explored.
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the prevention and control of HIV/AIDS and tubercu-
losis, but also to increased urbanisation and economic 
growth.2 3 Accordingly, as of 2011, NCDs are the leading 
cause of death in South Africa, which makes the preven-
tion and control of NCD paramount. Even though 
NCD disproportionally affects LMICs, these countries, 
including South Africa, often have limited capacity for 
the prevention and control of NCD.1 The rapid rise in 
NCDs is predicted to impede poverty reduction initiatives 
in low-income countries, particularly by increasing house-
hold costs associated with healthcare. Not much is known 
about the true economic and societal costs of NCDs in 
South Africa. The WHO recently estimated the loss of 
economic output associated with chronic diseases in 23 
LMICs. It was estimated that in South Africa between 
2006 and 2015, cumulative gross domestic product losses 
due to heart disease, stroke and diabetes alone amounted 
to US$1.88 billion.4
Rehabilitation can be defined as the ‘sum of activities 
required to influence favourably the underlying cause of 
the disease, as well as the best possible physical, mental 
and social conditions, so that they (patients) may by their 
own efforts, preserve or resume when lost, as normal a 
place as possible in the society’.5 The core components 
of rehabilitation for patients with NCD include base-
line patient assessment, educational interventions, risk 
factor modification, psychosocial interventions, physical 
activity counselling and exercise training.5–11 However, 
the unmet need for rehabilitation globally, and especially 
in LMICs is profound,12 13 and thought to be a direct 
function of the lack of reimbursement and governmental 
funding. The reasons are complex, and include health-
care budgetary issues (particularly for lower-income 
countries), inadequate legislation, lack of trained health-
care providers and a dearth of evidence from randomised 
controlled trials (RCTs) evaluating the effects of rehabili-
tation in LMICs such as those that are available in high-in-
come countries.14 While there is substantial evidence for 
the benefits of exercise-based rehabilitation in high-re-
source settings,15–18 the study, delivery and implementa-
tion of evidence-based rehabilitation in low-resourced 
settings are poorly understood. Hence, it is important 
to determine a minimalistic yet effective rehabilitation 
intervention and accompanying research methodology 
to optimise the (cost) benefits and sustainability of reha-
bilitation services in a low-resource setting.19 An effective, 
evidence-based, rehabilitation paradigm, specifically for 
resource-limited settings, is essential in terms of attaining 
United Nations’ sustainable development goal 3 ‘Ensure 
healthy lives and promote well-being for all at all ages’ 
in the context of an NCD epidemic.20 The role of reha-
bilitation is instrumental for effective implementation 
of a variety of global action plans including the Global 
Strategy and Action Plan on Ageing and Health (2016–
2020), and Framework on Integrated People-centred 
Health Services.12
A particularly important aspect regarding rehabilita-
tion in a low-resource setting, and in specifically in South 
Africa, is the influence of multiple comorbidities on the 
outcome of rehabilitation; that is, ‘quadruple burden of 
disease’ (communicable, non-communicable, perinatal 
and maternal, and injury-related disorders).2 21–23 Despite 
the widespread development of clinical practice guide-
lines, comorbidity remains a known barrier to the appli-
cation of such guidelines in various settings and across 
conditions.24 25 The robust evidence on which most clin-
ical practice guidelines are founded is primarily based 
on short-term RCTs, which exclude those with comorbid 
conditions.23 26 This limits the ability to generalise 
their results to settings with a high disease burden. For 
instance, a patient may present herself with simultaneous 
chronic obstructive pulmonary disorder and diabetes in 
the presence of an HIV infection with secondary cardio-
myopathy as a side effect of HIV treatment. Such complex 
patients argue against a ‘disease’-specific rehabilita-
tion approach (eg, cardiac rehabilitation and pulmo-
nary rehabilitation). Thus, there is a clear need for a 
patient-centred approach, incorporating the complexity 
of multiple comorbidities in a single-personalised rehabil-
itation programme. A study by Derman and colleagues on 
patient-centred rehabilitation for patients with NCD in a 
high-resource LMIC setting found significant improve-
ments in a variety of outcomes including lipid profile, 
muscle strength and walking capacity.27 However, the 
translation of this programme to a low-resource setting is 
limited due to the aforementioned quadruple burden of 
disease, but also setting-specific barriers and facilitators 
for treatment adherence (patient) and treatment fidelity 
(therapist). The transition to a patient-centred approach 
has been identified as the crux to the reimagined future 
of 2030 by the WHO through their #REHAB2030 call for 
action.12
The aim of this study is therefore to (i) test the 
feasibility28 and key characteristics of a minimalistic 
patient-centred rehabilitation intervention that is 
designed specifically for the low-resource setting and (ii) 
inform the research methodology and study design for a 
full-scale randomised clinical trial on the effectiveness of 
patient-centred rehabilitation for NCD in a low-resource 
setting.
These aims can be structured according to the following 
objectives:
 ► To assess the feasibility and acceptance of a minimal-
istic patient-centred rehabilitation programme in a 
low-resource setting.
 ► To assess recruitment processes including attrition, 
retention and study uptake to inform a definitive RCT.
 ► To assess the feasibility of using a postponed informa-
tion randomisation model in the context of a low-re-
source setting.
 ► To assess barriers and facilitators for treatment adher-
ence (patient) and fidelity (therapist and physician).
 ► To assess the clinical relevance and validity of various 
outcomes in a low-resource community to inform the 
selection of primary and secondary outcomes, and 
sample size calculations for a full-scale RCT.
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 ► To assess the feasibility of a patient-perspective 
economic evaluation in the context of a low-resource 
setting.
 ► To demonstrate proof of principle by gathering infor-




This is a randomised pilot study28 with blinded assess-
ments to evaluate the feasibility of a patient-centred life-
style rehabilitation programme in addition to usual care, 
compared with usual care alone, in a low-resource setting 
over the course of a 1-year timespan (2019).
setting 
Bishop Lavis is a densely populated, urban area—home 
to ~54 000 people living mostly in formal dwellings.29 
Only 66% of the economically active population (aged 
15–65 years) of this community is employed. Approx-
imately half of these (47%) earn between 0 and 544$ 
(purchase power parity) per household (average ~4.4 
dependents per household) per month.30 In contrast, the 
gross average monthly household wage in South Africa 
is ~3231$. The dominant types of occupation in Bishop 
Lavis are those classified as elementary occupations, 
for example, machine operators and assemblers, craft 
and related trades workers, and clerks. Crime rates in the 
area are high, with Bishop Lavis being in the top 10 of 
neighbourhoods in terms of murders, attempted murder, 
robbery and drug-related or gang-related crimes.31
The Bishop Lavis Rehabilitation Centre (BLRC) is a 
university-driven service learning centre that provides 
physiotherapy, occupational therapy, dietetics, as well 
as speech and language therapy to the community of 
Bishop Lavis and its surroundings. However, no structural 
patient-centred rehabilitation programme is in place for 
people with NCD. The BLRC was opened in January 1994 
as a collaboration between the University of Stellenbosch, 
the Provincial Administration of the Western Cape and 
the Bishop Lavis local authority.
Patient and public involvement
Patients were not directly involved in the design of 
this study; however, their input was voiced through the 
>25 year experience of the BLRC staff (see acknowledge-
ments) working in this environment. All components of 
this study, including intervention and assessments, have 
been tested using volunteers at the BLRC. Feedback 
with respect to study findings will be provided during a 
patient-information day on completion of this study.
Participants
Inhabitants of the Bishop Lavis community diagnosed 
with at least one of the four major NCDs, namely cardio-
vascular diseases (eg, heart failure and stroke), cancers, 
chronic respiratory diseases (including chronic obstruc-
tive pulmonary disorder) and diabetes will be recruited 
through the Bishop Lavis Day Care hospital physician 
and nursing staff for the study. This study will take place 
over 1 year between January 2019 and December 2019. 
Overseen by the family physician (MA) at the Bishop 
Lavis clinic, physician and nursing staff will determine 
eligibility of the patient based on the following eligibility 
criteria, as well as verify contact details.
1. Cardiovascular disease, cancer, diabetes and/or chron-
ic respiratory disease.
2. Stable medical condition.
3. Agree to be contacted by research team.
The eligible patient will subsequently be contacted by 
the assessor (BLF), who will provide an oral explanation 
of the study and if interested, invite the eligible patient 
for a baseline assessment. During baseline assessment, the 
assessor (BLF) will determine inclusion/exclusion based 
on the following criteria, and obtain written informed 
consent for the observational study at this stage (consent 
1) prior to any outcome measure testing.
Inclusion criteria
1. At least 18 years of age or older (ie, adult).
2. Able to perform some weight-bearing or non-weight-
bearing exercise.
3. Minimal of one confirmed diagnosis according to the 
WHO classification32 of cardiovascular disease (ICD: 
I0-99), chronic respiratory disease (ICD: J30-98), ma-
lignant neoplasms (ICD: C00-97) or diabetes (E10-E14; 
excluding those with complications [E10.2-E10.29, 
E11.2-E11.29, E12.2, E13.2-E13.29 and E14.2]).
Exclusion criteria
1. No generic contraindications for exercise training or 
disease-specific contraindications for exercise training 
(table 1).33
2. Other contraindications for exercise prescription as 
determined by the physiotherapist.
3. Structured exercise training at regular intervals (more 
than once per week) at a moderate-to-vigorous intensi-
ty in the previous 3 months.
4. Psychiatric concerns, substance abuse or known histo-
ry of violence that would jeopardise the safe conduct 
of this programme.
5. Pregnancy.
data management and randomisation logistics
Data collection and randomisation are facilitated through 
http://www. castoredc. com. Castor EDC is an intuitive 
and secure cloud-based electronic data capture platform 
that facilitates defined user roles, advanced monitoring, 
participant management and powerful calculations. 
Data storage is compliant with all relevant regulations 
including good clinical practice.
Randomisation is conducted using a postponed-in-
formation model (figure 1).34 35 After inclusion in the 
observational cohort study, an appointment is made for 
baseline assessment (1) and followed by the extended 
(additional to the inclusion screening) medical history. 
Demographics and outcomes will be evaluated by the 
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blinded assessor at the initial assessment. At this time, also 
follow-up assessments will be scheduled. Subsequently, the 
participant will be ‘silently’ (ie, unknowingly) randomised 
to being offered or not being offered the rehabilitation 
programme (consent 2) using a 3:1 centralised and 
concealed allocation scheme. The assessor (BLF) will 
trigger randomisation through Castor EDC online (but 
will not have access to the outcome), and the coordinating 
physiotherapist (AR) will contact the patient with the 
randomisation outcome to ensure blinding of the assessor. 
This procedure entails three potential outcomes:
1. The participant is not offered the rehabilitation pro-
gramme, and as such is unaware of its existence. The 
participant will remain in the observational arm.
2. The participant is offered the rehabilitation pro-
gramme but declines to consent to the rehabilitation 
programme. The participant will continue the study in 
the observational arm.
Figure 1 Study flow chart of postponed information model. Blinded follow-up assessments of all outcomes at 8 weeks, 
16 weeks postrandomisation. The 6-week rehabilitation programme starts ~2 weeks after randomisation to allow for logistical 
arrangements.
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3. The participant is offered the rehabilitation pro-
gramme and agrees to participate (consent 2). The 
participant will provide the second informed consent 
and is subsequently contacted by the physiotherapist 
to initiate the rehabilitation programme (based at the 
BLRC).
It is hypothesised that the postponed information 
model reduces the ethical boundaries to allocate patients 
to a control condition (as is the case in this specific 
setting, where structured rehabilitation for NCDs is 
non-existent), while maintaining the recruitment effi-
ciency and robustness of a conventional RCT.34 35 This 
model also ensures that a participant makes an informed 
decision to participate in an intervention, without the risk 
of being randomised to usual care, and therefore resem-
bles clinical practice more closely. It can be hypothesised 
that patients who provide the second consent to partic-
ipate in the rehabilitation programme are subsequently 
more motivated to engage in the intervention. It can 
be postulated that by resembling clinical practice more 
closely, translation from research into clinical practice is 
more likely. Finally, this model also allows the assessment 
of patients who decline to participate or discontinue the 
intervention, providing additional insights into the feasi-
bility of the intervention. The present study will therefore 
inform, through qualitative (eg, focus group interviews) 
and quantitative (eg, retention rate, acceptance rate) 
research techniques, whether or not a postponed informa-
tion model is a viable randomisation strategy and reduces 
some of the methodological constrains for conducting 
an RCT in a low-resource setting. Participants will be 
informed about the full extent of this model during a 
patient-information day on completion of the study.
outcomes and participant characteristics
Due to the feasibility nature of this RCT, no a-priori 
primary outcome is identified or power-analysis 
conducted. Outcomes have been selected based on 
their clinical relevance, pragmatic implementation in a 
low-resource setting and expected lack of dependency 
on the health-literacy of the patient. All outcomes will 
be assessed at baseline, 8 weeks postrandomisation (ie, 
postintervention) and 16 weeks postrandomisation by an 
assessor blinded to treatment allocation (see table 2 for 
the assessment schedule).
Participants’ characteristics
The following participants’ characteristics will be 
recorded to describe the study sample: demographics 
(eg, age), socioeconomic status and lifestyle-related 
factors (eg, smoking).
Medical history
A qualified physiotherapist (BLF) will take a detailed 
medical history, which is double checked offline against 
exclusion criteria by the family physician (MA). A disease 
severity classification is included in the medical history for 
cardiovascular disease,36 cancer (https:// cancerstaging. 
org) and diabetes (type 1 and type 2).37 Disease severity 
for chronic respiratory disease is determined after inclu-
sion, during the physical examination (according to the 
patient’s forced expiratory volume [FEV1]).
Physical examination and lifestyle inventory
Each participant will undergo a basic physical examina-
tion by the assessor who is blinded to treatment allocation 
during follow-up assessments. The examination includes 
the measurement and recording of height (m), weight 
(kg), hip and waist circumference (cm), resting blood 
pressure (mm Hg), lung spirometry (FEV and Force Vital 
Capacity) and resting heart rate (beats per minute). Life-
style risk factors including tobacco consumption (one 
selected item), alcohol consumption (one selected item), 
diet (four items), and selected items from the violence 
module (two items), will be assessed using components of 
the WHO STEPS instrument.38 Separate questionnaires 
are included for physical activity and quality of sleep.
Physical activity
The International Physical Activity Questionnaire (IPAQ) 
is a 27-item self-reported measure of physical activity for 
use with individual adult patients aged 15–69 years old. 
Duration (minutes) and frequency (days) of physical 
activity in the last 7 days is measured in domains of job-re-
lated, transportation, housework, house maintenance, 
caring for family, recreation, sport and leisure-time, and 
time spent sitting. The IPAQ has acceptable psychometric 
properties relative to other self-report measures.39
Quality of sleep
Quality of sleep is assessed using the Pittsburgh Sleep 
Quality Index (PSQI). The PSQI differentiates ‘poor’ 
from ‘good’ sleep quality by measuring seven areas 
(components): subjective sleep quality, sleep latency, 
sleep duration, habitual sleep efficiency, sleep distur-
bances, use of sleeping medications and daytime dysfunc-
tion over the last month. The PSQI has shown moderate 




The primary mode of transport for most people living 
in a low-resource setting (eg, Bishop Lavis) is walking.29 
It is evident that having one or more NCDs has a severe 
impact on mobility, and therefore daily life and participa-
tion. The six-minute walk test (6MWT) has been shown to 
be a valid, reliable and responsive measure across various 
patient groups.41 The 6MWT is a functional walking test 
that requires the participant to walk around a measured 
and demarcated (eg, pylons or coloured tape to mark 
turning points) 30 m track for 6 min continuously when 
conducted in accordance with published guidelines.42 
Due to resource-constraints (space), a 10 m lap distance 
will be used instead. The 6MWT will be conducted twice 
during baseline testing to reduce the learning effect, 
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which has been reported to be as large as 27–35 m in 
patients with chronic heart failure.43
Timed up and go test
The timed up and go (TUG) test is a measure of function 
which closely corresponds with balance and fall risk.44 The 
participant is asked to stand up from an armed chair, walk 
3 m and return to the chair as quickly as they feel safe and 
comfortable. Each participant will get one practice run, and 
two runs that count. The best run is used as the outcome. 
The test has shown excellent test–retest reliability (Intra-
class Correlation[ICC} Coefficient=0.93), and moderate 
concurrent validity with the 6MWT (r=−0.81).45
Six-spot step test
The six-spot step test (SSST) is a relatively new quantita-
tive test of ambulation with components of coordination, 
dynamic balance and lower-limb function.46 47 The SSST 
is performed in a 5 m rectangular field with five marked 
circles (diameter 20 cm) which contain a wooden block 
(4×8 cm2, 140 g).47 From the starting line, the participant 
is instructed to walk to the other side as quickly as safe 
and comfortable, kicking the wooden blocks out of the 
circles in the process. The assessor first provides a demon-
stration, after which the participant does two runs with 
the dominant and two with the non-dominant leg. The 
SSST combines straight walking with bouts of single-leg 
standing (during kicking), making it unique from other 
common walking tests (including 6MWT and TUG).
health-related quality of life (EQ-5d-5l)
The EQ-5D-5L is a 5-item, self-report questionnaire 
to assess self-care, mobility, pain/discomfort, anxiety/
depression and usual activities on a 1–5 scale of perceived 
problems in these domains. In addition, general health 
is scored using a visual-analogue-scale. Combined, these 
six items form a profile of health-related quality of life. 
The EQ-5D-5L is essential in terms of the economic eval-
uation. The EQ-5D-5L is widely used and validated in a 
surplus of chronic medical conditions, most recently in a 
large cohort of the elderly.48
Cost–benefits
While the provider-perspective economic evaluation 
is generally feasible in a low-resource setting (eg, clin-
ical record review), most studies conducted in a low-re-
source setting refrain from economic evaluations from a 
patient-perspective. In the present study, we aim to test the 
feasibility of a patient-perspective economic evaluation 
in addition to key provider statistics (personnel, equip-
ment, inpatient visits, outpatient visits and drug use). 
To that extent, the following outcomes will be included: 
direct costs related to transportation (patient or care-
giver), direct medical costs (ie, over the counter drugs 
and supplements), strategies to pay for out-of-pocket 
expenses (ie, medical poverty trap)49 and patient-re-
ported productivity costs based on the Productivity Cost 
Questionnaire.50 51
treatment adherence and fidelity
Each patient will keep a paper and pen-based exercise 
diary/file in which the moderate-to-vigorous physical 
activity and resistance exercises are logged, if applicable 
photos are added to illustrate proper execution of the 
exercises and patients keep note of the extent (frequency, 
duration, intensity and repetitions) to which they have 
completed their physical activity targets and prescribed 
resistance exercises (see programme description below). 
These records will then be reviewed during each super-
vised session, and where necessary, the patient will be 
encouraged to improve his/her adherence. Barriers that 
limit adherence will be recorded.
Treatment fidelity practices are related to study design, 
training providers and delivery of treatment.52 53 To opti-
mise fidelity of treatment provision, all treatment providers 
will receive a 1-day training, which will cover the study 
protocol, and considerations for exercise-based rehabil-
itation in cardiovascular disease, cancer, chronic respira-
tory disease and diabetes. The standardised training will 
reduce the likelihood of a provider×treatment interac-
tion. Adherence to the prescribed intervention from a 
patient perspective is recorded during the intervention 
(frequency, dose and intensity). Participants will receive a 
‘graduation diploma’ if they complete and adhere to 90% 
of the supervised exercise and education sessions. During 
the conduct of the intervention, providers will sign-off on 
the delivered components of the intervention following 
each session. An independent physiotherapist will review 
10% of the therapy sessions, convene with the therapy 
provider to ensure protocol adherence and address 
potential provider differences due to level of education, 
skill level or background.
the patient-centred rehabilitation programme
There is no consensus as to the minimum duration of 
an exercise-based rehabilitation programme to lead 
to clinically relevant improvements. However, rehabil-
itation programmes as short as 3–5 weeks have shown 
clinical relevant improvements walking capacity (mean 
difference=30.9 m, 95% CI 9.4 to 52.4, p=0.005).54 55 
Rather than the duration per se, the effectiveness of exer-
cise-based rehabilitation should mostly be attributed to 
the extent the exercises are specific for the desired goal, 
and to the extent in which the exercises and dose are indi-
vidualised to the patients’ functional capacity at baseline 
and progresses over time. In the present study, we aim 
to develop a treatment paradigm that, on the one hand, 
potentially results in clinically relevant and sustained 
improvements in body function, activity and participa-
tion, while, on the other hand, keeping the cost–benefits 
optimal. To that end, the rehabilitation programme for 
the present feasibility study has been limited to 6 weeks, 
designed with respect to the anticipated difficulties 
related to the low-resource setting,56 while still addressing 
the core components of rehabilitation in terms of risk 
factor analysis, exercise and patient-education.57
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Exercise component
The rehabilitation programme will start ~2 weeks after 
randomisation to allow for appropriate scheduling. The 
supervised exercise prescription will be tailored to each 
patient’s initial functional capacity, profile of comorbidi-
ties, use of medication and active disease status and consist 
of an aerobic and resistance component. The exercise 
component of the intervention will consist of one 60 min 
supervised group session (max five per group) per week, 
and two 30 min home-based sessions, and will progress in 
terms of intensity throughout the 6 weeks according to 
the patient’s (increasing) ability. Each group session will 
entail a 10 min group-based warm-up, 20 min aerobic-type 
training with a specific educational component (see 
below) and 30 min of resistance training. Even though 
the supervised sessions are group-based, each patient 
will follow his or her own individualised, patient-centred, 
exercise programme. Group sessions will be offered once 
daily. Participants need to sign-up at which timeslot they 
wish to attend the following week. It is hypothesised that 
by giving the participant this flexibility, and given antici-
pated barriers related to the low-resource setting, adher-
ence to the supervised sessions will be higher.
The primary exercise component is to enable the patient 
to be health-enhancing, moderately-to-vigorously active, 
five times a week for 30 min or a combined minimum of 
150 min/week in a home environment, at completion of 
the 6-week intervention, in accordance with the Amer-
ican College of Sports Medicine (ACSM) guidelines for 
physical activity.33 To ascertain this goal, each supervised 
60 min practical exercise sessions has a specific theme 
(see box 1).
It is hypothesised that by introducing an educational 
theme to the supervised aerobic exercise component, this 
relatively short rehabilitation programme is more likely 
to result in sustainable benefits.
The secondary exercise component will entail the 
participants engaging in two-to-three progressive resis-
tance type exercises, involving large muscle groups for 
improving specific muscle and/or gait function. This is in 
line with recent suggestions for a stronger focus on resis-
tance training (compared with higher intensity aerobic 
exercise-based rehabilitation) might be a more viable 
paradigm to improve health outcomes.58 Resistance 
training exercises can be general exercises to improve 
stability, balance or muscle strength or can be more spec-
ified to the health condition, for instance in patients with 
hemiplegia or respiratory muscle weakness. Progression 
and intensity of exercise are based on the aim (eg, muscle 
strength, endurance and power) in accordance with the 
ACSM guidelines for resistance training (table 3). Each 
participant will be requested to keep a paper-based exer-
cise diary during the intervention phase. All prescribed 
exercises, both aerobic as well as resistance type exercises, 
should be viable with no or minimal equipment.59 Leaf-
lets will be handed out to the participants with preferred, 
key exercises to promote proper conduct of the exercise 
in a home-environment.
Educational component
Each patient will be requested to enrol in each of the three 
educational sessions through the course of the 6-week 
programme to facilitate informed healthy choices.57 Topic 
one will be presented during week 1 of the intervention, 
topic two during week 3 and topic three during week 6. 
Each topic will be presented daily throughout that week 
and patients can sign-up according to their availability. It 
is hypothesised that providing this flexibility, adherence 
will be higher. Each session consisted of a 15–30 min stan-
dardised educational part, and a 15–30 min group discus-
sion to enable vicarious learning (ie, learning by the 
experiences of peers)60 and address perceived facilitators 
and barriers with respect to the subject at hand.
1. NCDs of lifestyle.
2. Heart-health behaviour (eg, tobacco-use and nutri-
tion).
3. Health benefits of physical activity.
usual care
Usual care at the Bishop Lavis Day Clinic is directed mainly 
towards ongoing medical management of community 
members with chronic disease. Referral to the (in-house) 
rehabilitation centre is limited, and not standardised. 
An optional education session for patients with NCD is 
hosted monthly, with shifting themes.
sample size
There are no precise estimates on the prevalence of NCD 
in Bishop Lavis per se. However, results from the Global 
Health Action indicate a prevalence of ~52% NCDs in 
South Africa.61 Approximately 22% of these patients 
reported the presence of ≥2 chronic conditions. Among 
others, cultural background and living in an urban area 
are considered risk factors for a higher prevalence of 
NCD. If we translate these numbers to the Bishop Lavis 
community (54 006 inhabitants), one may estimate that 
the population of people with NCD is roughly 28 083. 
It is hypothesised that using the 3:1 allocation (offer vs 
non-offer) ratio, this will approximately result into a 1:1 
group allocation; in other words, for every three patients 
who will be offered the rehabilitation programme, two will 
consent and one will decline. The study will be conducted 
box 1 six different themes addressed during the 
supervised exercise sessions
1. Exercise and safety; recognising body responses to exercise and 
safety warnings.
2. Home-based exercise options.
3. What entails moderate intensity exercise (individualised moderate 
intensity reference).
4. What entails vigorous intensity exercise (individualised upper inten-
sity reference).
5. Alternative community exercise modalities.
6. Long-term goal setting–continuing a physically active lifestyle.
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over the course of 1 year, with the final group starting in 
week 40. As such, recruitment, reasons for non-participa-
tion or adherence can be evaluated within the context 
of an entire year (eg, seasonal changes). The theoretical 
maximum capacity of the programme is 25 patients per 
week, five complete treatment cycles of 8 weeks within 40 
weeks, leading to 125 patients in the experimental group.
data analysis
 ► The feasibility of the postponed-information model 
and recruitment strategy in a low-resource setting 
will be evaluated quantitatively based on the eligible 
patients, participant and retention rate, group-alloca-
tion ratio, drop-out rate and treatment adherence.
 ► Treatment fidelity is assessed by reviewing 10% of the 
provided treatment sessions against the study protocol 
by an independent rehabilitation specialist.
 ► Feasibility of the different treatment components is 
assessed by reviewing the training dairies and adher-
ence rates for both the supervised exercise sessions, as 
well as education sessions.
 ► Feasibility of the various endpoints is assessed by 
performing a preliminary longitudinal data-analysis 
(ie, random-coefficient analysis or generalised esti-
mating equations) to determine the time-by-group 
interaction for each outcome measure and based 
on an intention-to-treat principle. It has been shown 
that both these longitudinal data techniques are 
robust to missing data in the analysis of continuous 
outcomes.62 63 If appropriate, analyses will be adjusted 
for patient characteristics that differ between the two 
groups. Independent variables (covariates) can be 
added to the model to assess and estimate their impact 
on the dependent variable. Among others, this may 
include the overall treatment adherence to estimate 
the extent in which protocol deviations may bias the 
results. The longitudinal analysis will be performed 
blinded to treatment allocation.
 ► Acceptance of the programme is evaluated using 
group-based focus interviews with both participants 
of the intervention and participants that declined the 
intervention.
EthICs And dIssEMInAtIon
All of the participants will be recruited through volun-
tary participation, and written informed consent forms 
from all trial participants will be obtained by researchers 
in accordance with the Declaration of Helsinki.64 Each 
participant will receive a unique identifier to ensure 
confidentiality before, during and after the trial.
safety
Patients will be asked to report any adverse events (AEs) 
during the home-based training at each supervised 
session. All AEs that occur during testing or rehabilitation 
treatment will be recorded and reviewed by the medical 
practitioner to determine seriousness and relation to the 
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AEs during the home-based training at each supervised 
session. Muscle soreness and increased levels of a fatigue 
are only reported as AEs if lasting >48 hours. Serious 
AEs will be expedited to the medical ethics committee as 
per good clinical practice. This study is covered by Stel-
lenbosch University’s no-fault study insurance, a medical 
doctor is on the study team, and both testing and super-
vised treatment are conducted in a hospital environment, 
ensuring prompt and adequate treatment of any issues or 
injuries arising during the conduct of the study.
reimbursement of participants
Each participant will receive a monetary token for partic-
ipating in this study to the value of R100 per completed 
assessment visit (R300 in total per participant). There 
are a number of arguments to justify the amount per 
visit. First, given the low-resource environment (average 
income of ZAR1600/month) of the Bishop Lavis commu-
nity, a higher reimbursement will substantially increase 
the likelihood of undue influence in signing informed 
consent. Second, all visits (assessment and treatment) 
will take place within the Bishop Lavis community, 
substantially reducing the time, inconvenience and travel 
requirements. Third, the inconvenience of the assessment 
battery is reduced to a minimum and does not entail inva-
sive procedures. No reimbursement will be provided for 
the supervised treatment visits (n=6[exercise]+3[education]). 
First, this will increase the undue influence for patients 
to sign consent based on the monetary revenue it would 
entail. But more importantly, this will significantly limit 
the ecological validity, sustainability and implementation 
of the rehabilitation model studied into clinical practice, 
if shown feasible.
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16/05/2018                                                           
Project ID : 0913 
HREC Reference #: M17/09/031   
Title: Patient-centred lifestyle rehabilitation for management of non-communicable disease in a low-resource setting: a randomized pilot study 
 
Dear Dr Martin Heine, 
The Response to Deferral received on 13/04/2018 10:48  was reviewed at a convened meeting of Health Research Ethics Committee 2
(HREC2)  on 16/05/2018   and was approved.
Please note the following information about your approved research protocol:
Protocol Approval Period: This project has approval for 12 months from the date of this letter.
Please remember to use your Project ID  [0913] on any documents or correspondence with the HREC concerning your research protocol.
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require further modifications, or
monitor the conduct of your research and the consent process.
After Ethical Review 
Please note you can submit your progress report through the online ethics application process, available at: Links Application Form Direct
Link  and the application should be submitted to the HREC before the year has expired. Please see Forms and Instructions on our HREC website
(www.sun.ac.za/healthresearchethics) for guidance on how to submit a progress report.
The HREC will then consider the continuation of the project for a  further year (if necessary). Annually a number of projects may be selected
randomly for an external audit.
Provincial and City of Cape Town Approval
Please note that for research at a primary or secondary healthcare facility, permission must still be obtained from the relevant authorities (Western
Cape Departement of Health and/or City Health) to conduct the research as stated in the protocol. Please consult the Western Cape Government
website for access to the online Health Research Approval Process, see: https://www.westerncape.gov.za/general-publication/health-research-
approval-process. Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics
approval is required BEFORE approval can be obtained from these health authorities.
We wish you the best as you conduct your research.
For standard HREC forms and instructions, please visit: Forms and Instructions on our HREC
website https://applyethics.sun.ac.za/ProjectView/Index/913  





Health Research Ethics Committee 2 (HREC2).
National Health Research Ethics Council (NHREC) Registration Number:
REC-130408-012 (HREC1)·REC-230208-010 (HREC2)
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Stellenbosch University https://scholar.sun.ac.za
Federal Wide Assurance Number: 00001372
Office of Human Research Protections (OHRP) Institutional Review Board (IRB) Number:
IRB0005240 (HREC1)·IRB0005239 (HREC2)
 
The Health Research Ethics Committee (HREC) complies with the SA National Health Act No. 61 of 2003 as it pertains to health research. The
HREC abides by the ethical norms and principles for research, established by theWorld Medical Association (2013). Declaration of Helsinki:
Ethical Principles for Medical Research Involving Human Subjects;the South African Department of Health (2006). Guidelines for Good
Practice in the Conduct of Clinical Trials with Human Participants in South Africa (2nd edition); as well as the Department of Health
(2015). Ethics in Health Research: Principles, Processes and Structures (2nd edition).
 
The Health Research Ethics Committee reviews research involving human subjects conducted or supported by the Department of Health and
Human Services, or other federal departments or agencies that apply the Federal Policy for the Protection of Human Subjects to such research
(United States Code of Federal Regulations Title 45 Part 46); and/or clinical investigations regulated by the Food and Drug Administration
(FDA) of the Department of Health and Human Services.
 




Project ID: 0913 
Ethics Reference #: M17/09/031  
Title: Patient-centred lifestyle rehabilitation for non-communicable disease in a low-resource setting: a feasibility and proof-of-concept randomized
clinical trial<br> 
Dear Dr Martin Heine ,
Your amendment request and the response to the requested modifications dated 12 September 2018 refer.
The Health Research Ethics Committee (HREC) reviewed and approved the amended documentation through an expedited review process.
 
The following amendments were reviewed and approved:
1. Amended Protocol Version 3 Dated 28 August 2018
2. Translated Informed Consent Forms in Afrikaans (part 1 and 2)
3. Health Passport
4. Addition of Mrs Brittany Fell to the Research Team as a Sub-Investigator (Research Assistant).
Where to submit any documentation
Kindly note that the HREC uses an electronic ethics review management system, Infonetica, to manage ethics applications and ethics review
process. To submit any documentation to HREC, please click on the following link: https://applyethics.sun.ac.za.
 
Please remember to use your Project ID [0913] and ethics reference number  [M17/09/031] on any documents or correspondence with the HREC
concerning your research protocol.
 
National Health Research Ethics Council (NHREC) Registration Numbers: REC-130408-012 for HREC1 and REC-230208-010 for HREC2
Federal Wide Assurance Number: 00001372
Institutional  Review Board (IRB) Number: IRB0005240 for HREC1
Institutional  Review Board (IRB) Number: IRB0005239 for HREC2
 
The Health Research Ethics Committee complies with the SA National Health Act No. 61 of 2003 as it pertains to health research and the United
States Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by the
Declaration of Helsinki and the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles,
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Project ID: 0913 
Ethics Reference #: M17/09/031 
Title: Patient-Centred Rehabilitation for non-communicable disease in a Low-Resource Setting: a feasibility and proof-of-concept randomized
clinical trial 
 
Dear Dr Martin Heine,
Your request for extension/annual renewal of ethics approval dated 06/02/2019 12:44  refers.
The Health Research Ethics Committee (HREC) reviewed and approved the annual progress report you submitted at a convened meeting of
HREC2 on 20 February 2019.
The approval of this project is extended for a further year.
Approval date: 20 February 2019
Expiry date: 19 February 2020
Kindly be reminded to submit progress reports two (2) months before expiry date. 
Where to submit any documentation
Kindly note that the HREC uses an electronic ethics review management system, Infonetica, to manage ethics applications and ethics review
process. To submit any documentation to HREC, please click on the following link: https://applyethics.sun.ac.za.
 
Please remember to use your Project ID [0913] and Ethics Reference Number [M17/09/031] on any documents or correspondence with the
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Office of Human Research Protections (OHRP) Institutional Review Board (IRB) Number:
IRB0005240 (HREC1)·IRB0005239 (HREC2)
 
The Health Research Ethics Committee (HREC) complies with the SA National Health Act No. 61 of 2003 as it pertains to health research. The
HREC abides by the ethical norms and principles for research, established by theWorld Medical Association (2013). Declaration of Helsinki:
Ethical Principles for Medical Research Involving Human Subjects;the South African Department of Health (2006). Guidelines for Good
Practice in the Conduct of Clinical Trials with Human Participants in South Africa (2nd edition); as well as the Department of Health
(2015). Ethics in Health Research: Principles, Processes and Structures (2nd edition).
 
The Health Research Ethics Committee reviews research involving human subjects conducted or supported by the Department of Health and
Human Services, or other federal departments or agencies that apply the Federal Policy for the Protection of Human Subjects to such research
(United States Code of Federal Regulations Title 45 Part 46); and/or clinical investigations regulated by the Food and Drug Administration
(FDA) of the Department of Health and Human Services.
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Project ID: 0913 
Ethics Reference No: M17/09/031 
Project Title:  Patient-centred lifestyle rehabilitation for non-communicable disease in a low-resource setting: a feasibility and proof-of-concept
randomized clinical trial 
Dear Dr Martin Heine, 
Your amendment request dated 11 September 2019 refers.
The Health Research Ethics Committee (HREC) reviewed and approved the amended documentation through an expedited review process.
The following amendments were reviewed and approved:
1. Amended DEF_protocol version 3.0 dated 11 September 2019
2. Additions of Dr Mumtaz Abbas as co-investigator and Miss Ashleigh Robinson as a Research Assistant (Physiotherapist) to the study team.
Where to submit any documentation
Kindly note that the HREC uses an electronic ethics review management system, Infonetica, to manage ethics applications and ethics review
process. To submit any documentation to HREC, please click on the following link: https://applyethics.sun.ac.za.
Please remember to use your Project ID [0913] andethics reference number [M17/09/031] on any documents or correspondence with the HREC
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The Health Research Ethics Committee (HREC) complies with the SA National Health Act No. 61 of 2003 as it pertains to health research. The
HREC abides by the ethical norms and principles for research, established by the
World Medical Association (2013). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects;the South
African Department of Health (2006). Guidelines for Good Practice in the Conduct of Clinical Trials with Human Participants in South
Africa (2nd edition); as well as the Department of Health (2015). Ethics in Health Research: Principles, Processes and Structures (2nd edition).
 
The Health Research Ethics Committee reviews research involving human subjects conducted or supported by the Department of Health and
Human Services, or other federal departments or agencies that apply the Federal Policy for the Protection of Human Subjects to such research
(United States Code of Federal Regulations Title 45 Part 46); and/or clinical investigations regulated by the Food and Drug Administration
(FDA) of the Department of Health and Human Services. 
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Printed on 04-12-2020 11:22:44 by Martin Heine
1. Inclusion - Inclusion
Number Question Answers
1.1 Please provide todays date:    (dd-mm-yyyy)
1.2 Date of Birth    (dd-mm-yyyy)
1.3 Sex  Male
 Female
1.4 Age 
Exclude patient if field's value is
smaller than 18 with message:
'Exclude patient' 
1.5 Day hospital file available during
inclusion (if applicable)? 
 Yes
 No
1.6 Does the patient has one or more of
the following medical conditions?
(tick all that apply) 
Exclude patient if field's value is
equal to No with message: 'Please
complete other in/exclusion criteria
prior to excluding the patient from
study participation' 
 Cardiovascular disease (ICD: I0-99)
 Cancer (ICD: C00-97)
 Chronic Respiratory Disease (ICD:J30-98)
 Diabetes (E10-E14; excluding those with complications)
 No
1.6.1 If 'Does the patient has one or
more of the following medical
conditions? (tick all that apply)' is
equal to 'Cardiovascular disease
(ICD: I0-99)' answer this question: 
Please specify the Cardiovascular
Disease 
0 1 2 3 4
CVD 1 --- ---
CVD 2 --- ---





1.6.2 If 'Does the patient has one or
more of the following medical
conditions? (tick all that apply)' is
equal to 'Chronic Respiratory
Disease (ICD:J30-98)' answer this
question: 
Please specify the Chronic
Respiratory Disease 




Row Number 4 ---
1.6.3 If 'Does the patient has one or
more of the following medical
conditions? (tick all that apply)' is
equal to 'Cancer (ICD: C00-97)'
answer this question: 
Please specify the Cancer 











1.6.4 If 'Does the patient has one or 0 1 2 3
Stellenbosch University https://scholar.sun.ac.za
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more of the following medical
conditions? (tick all that apply)' is




Please specify the Diabetes 
Diabetes ---
1.7 Is the patient able to perform in
some weight-bearing or non-weight-
bearing exercise? 
Exclude patient if field's value is
equal to No with message: 'Please
complete other in/exclusion criteria
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2. Inclusion - Exclusion
Number Question Answers
2.1 If 'Sex' is equal to 'Female' answer this question: 
Is the patient currently pregnant? 
Exclude patient if field's value is equal to Yes with message: 'Please




2.2 Did the patient engage in structured exercise training at regular intervals
(more than once per week) at a moderate-to-vigorous intensity in the
previous 3 months? 
Exclude patient if field's value is equal to Yes with message: 'Please




2.3 Are there strict contraindications for physical activity participation?  No
 Recent (2 days) significant ischemia, myocardial
infarction, or other acute cardiac event
 Unstable angina
 Uncontrolled cardia dysrhythmias causing symptom or
hemodynamic compromise
 Symptomatic severe aortic stenosis
 Uncontrolled symptomatic heart failure
 Acute myocarditis or pericarditis
2.4 Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that warrant
exclusion from this study? 
 Electrolyte abnormalities
 Severe arterial hypertension (SBP > 200mmHg and/or
DBP > 110 mmHg) at rest
 Neuromuscular, musculoskeletal, or rheumatoid
disorders that are exacerbated by exercise
 Physical impairment leading to inability to exercise
adequately
 Acute systemic infection, accompanied by fever, body
aches, or swollen lymph glands
 Uncontrolled metabolic disease (e.g. diabetes,
thyrotoxicosis, or myxoedema)
 Chronic infectious disease (e.g. mononucleosis,
hepatitis, AIDS)
 Left main coronary stenosis
 Moderate stenotic valvular heart disease
 Tachydysrhytmia or bradydysrythmia
 Hyperthrophic cardiomyopathy and other forms of
outflow tract obstruction
 Acute pulmonary embolus or pulmonary infection
 Suspected or known dissecting aneurysm
 Mental impairment leading to inability to exercise
adequately (i.e. neglect, aphasia, severe depression)
2.4.1 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Electrolyte




2.4.2 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Severe arterial
hypertension (SBP > 200mmHg and/or DBP > 110 mmHg) at rest'
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Warrants exclusion? 
2.4.3 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Neuromuscular,
musculoskeletal, or rheumatoid disorders that are exacerbated by




2.4.4 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Physical impairment




2.4.5 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Acute systemic
infection, accompanied by fever, body aches, or swollen lymph glands'




2.4.6 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Uncontrolled metabolic





2.4.7 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Chronic infectious




2.4.8 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Left main coronary




2.4.9 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Moderate stenotic




2.4.10 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Tachydysrhytmia or




2.4.11 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Hyperthrophic





2.4.12 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Acute pulmonary
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Warrants exclusion? 
2.4.13 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Chronic infectious




2.4.14 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Suspected or known




2.4.15 If 'Based on your clinical opinion, are any of the following general
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Mental impairment
leading to inability to exercise adequately (i.e. neglect, aphasia, severe




2.5 If 'Does the patient has one or more of the following medical
conditions? (tick all that apply)' is equal to 'Cardiovascular disease
(ICD: I0-99)' answer this question: 
Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that warrant
exclusion from this study? 
 Uncontrolled hypertension (ie. SBP > 180 and/or DBP >
110) at rest
 Orthostatic BP drop > 20 mmHg with symptoms
 Acute systemic illness or fever
 Uncontrolled diabetes mellitus
 Other metabolic conditions such as acute thyroiditis,
hypokalemia, hyperkalemia, or hypovolemia.
 Critical aortic stenosis (ie. peak SBP gradient of >50
mmHg with an aortic valve orifice area of <0.74cm2 in an
average size adult)
 Uncontrolled atrial or ventricular dysrythmias
 Uncontrolled sinus tachycardia (>120bpm)
 Uncompensated chronic heart failure
 Third degree atrioventricular (AV) block without
pacemaker
 Active pericarditis or myocarditis
 Resting ST-segment depression or elevation (>2mm)
 Recent embolism
 Thrombophlebitis
2.5.1 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Uncontrolled





2.5.2 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Orthostatic BP drop >




2.5.3 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Acute systemic illness




2.5.4 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
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mellitus' answer this question: 
Warrants exclusion? 
2.5.5 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Other metabolic
conditions such as acute thyroiditis, hypokalemia, hyperkalemia, or




2.5.6 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Critical aortic stenosis
(ie. peak SBP gradient of >50 mmHg with an aortic valve orifice area of




2.5.7 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Uncontrolled atrial or




2.5.8 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Uncontrolled sinus




2.5.9 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Uncompensated




2.5.10 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Third degree




2.5.11 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Active pericarditis or




2.5.12 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Resting ST-segment




2.5.13 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Recent embolism'




2.5.14 If 'Based on your clinical opinion, are any of the following CVD-specific
contraindications for physical activity participation present that
warrant exclusion from this study?' is equal to 'Thrombophlebitis'
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2.6 If 'Does the patient has one or more of the following medical
conditions? (tick all that apply)' is equal to 'Cancer (ICD: C00-97)'
answer this question: 
Based on your clinical opinion, are any of the following Cancer-specific
contraindications or physical activity participation present that warrant
exclusion from this study? 
 Severe tissue reaction to radiation therapy
 Platelets <50000
 White blood cells < 3000
 Haemoglobin < 10 mg/dl
 Bone, back or neck pain of recent origin
 Unusual muscular weakness
 Severe cachexia
 Unusual / extreme fatigue
 Poor functional status
 Acute infections
 Febrile illness: fever > 38 degrees
 General malaise
 Resting SBP > 145mmHg and/or DBP > 95 mmHg
 Severe nausea
 Vomiting or diarrhea within 24-36 hours
 Dehydration
 Poor nutrition: inadequate fluid and/or food intake
 Chest pain
 Resting HR > 100bpm or < 50bpm
 Irregular heart rate
 Swelling of ankles
 Severe dyspnea
 Cough, wheezing
 Chest pain increased with deep breath
 Significant decline in cognitive status
 Dizziness / light headedness
 Disorientation
 Blurred vision
 Ataxia (ie. inability to coordinate voluntary movement)
2.6.1 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Severe tissue reaction




2.6.2 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Platelets <50000'




2.6.3 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'White blood cells <




2.6.4 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Haemoglobin < 10




2.6.5 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Bone, back or neck




2.6.6 If 'Based on your clinical opinion, are any of the following Cancer-  Yes
Stellenbosch University https://scholar.sun.ac.za
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specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Unusual muscular
weakness' answer this question: 
Warrants exclusion? 
 No
2.6.7 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Severe cachexia'




2.6.8 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Unusual / extreme




2.6.9 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Poor functional status'




2.6.10 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Acute infections'




2.6.11 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Febrile illness: fever >




2.6.12 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'General malaise'




2.6.13 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Resting SBP >




2.6.14 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that





2.6.15 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Vomiting or diarrhea




2.6.16 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
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2.6.17 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Poor nutrition:




2.6.18 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that





2.6.19 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Resting HR > 100bpm




2.6.20 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Irregular heart rate'




2.6.21 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Swelling of ankles'




2.6.22 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Severe dyspnea'




2.6.23 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Cough, wheezing'




2.6.24 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Chest pain increased




2.6.25 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Significant decline in




2.6.26 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Dizziness / light




2.6.27 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
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Warrants exclusion? 
2.6.28 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that





2.6.29 If 'Based on your clinical opinion, are any of the following Cancer-
specific contraindications or physical activity participation present that
warrant exclusion from this study?' is equal to 'Ataxia (ie. inability to




2.7 If 'Does the patient has one or more of the following medical
conditions? (tick all that apply)' is equal to 'Diabetes (E10-E14;
excluding those with complications)' answer this question: 
Is there a presence of uncontrolled diabetes (i.e. blood glucose > 250 mmol
and presence of ketones; or HbAC1 > 7.0%) 
 Yes
 No
2.8 Is there a known history of psychiatric disorders, substance abuse or
violence that would jeopardize the safe conduct of this program? 
Exclude patient if field's value is equal to Yes with message: 'Please




2.9 Based on your clinical opinion, are there any other reasons for this patient
not to participate in this study? 
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3. Inclusion - Consent 1
Number Question Answers
3.1 Please confirm that the patient has met the in / exclusion criteria 




3.2 Please confirm that oral and written consent to the observational part of this
study have been obtained (consent 1) 
 Yes
 No
3.3 Version:  V1 (Afrikaans)
 V1 (English)
3.2.1 If 'Please confirm that oral and written consent to the observational
part of this study have been obtained (consent 1)' is equal to 'Yes'
answer this question: 
Surname 
3.2.2 If 'Please confirm that oral and written consent to the observational
part of this study have been obtained (consent 1)' is equal to 'Yes'
answer this question: 
First name 
3.2.3 If 'Please confirm that oral and written consent to the observational
part of this study have been obtained (consent 1)' is equal to 'Yes'
answer this question: 
Primary contact number 
3.2.4 If 'Please confirm that oral and written consent to the observational
part of this study have been obtained (consent 1)' is equal to 'Yes'
answer this question: 
Emergency contact 
3.2.5 If 'Please confirm that oral and written consent to the observational
part of this study have been obtained (consent 1)' is equal to 'Yes'
answer this question: 
Email (if available) 
3.2.6 If 'Please confirm that oral and written consent to the observational
part of this study have been obtained (consent 1)' is equal to 'Yes'
answer this question: 
WCDOH file number 
3.2.7 If 'Please confirm that oral and written consent to the observational
part of this study have been obtained (consent 1)' is equal to 'Yes'




Page 57 of 76https://data.castoredc.com/print-crf/E8704677-2E2B-0B13-A42A-9…ates=0&includeHiddenCalculationFields=1&stepsOnSeparatePages=1
30. Follow-up 2 (16 weeks) - Testing conditions
Number Question Answers
30.1 Temperature in hour before assessment  Degrees Celcius
30.2 Rain forecast in hour prior to assessment  mm
30.3 Test setting for 6MWT and SSST  Inside
 Outside
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31. Follow-up 2 (16 weeks) - Physical Examination
Number Question Answers
31.1 Body weight?  Kg
31.2 Height?  cm
31.3 Body Mass Index: 
31.4 Waist circumference  cm
31.5 Hip circumference  cm
31.6 Waist to Hip ratio 
31.7 WHR chart 
Resting blood pressure and heart rate; Please have the patient seated, in rest, for 5 minutes prior to assessment












31.10 If 'Does the patient has one or more of the following medical
conditions? (tick all that apply)' is equal to 'Diabetes (E10-E14;
excluding those with complications)' answer this question: 
Blood glucose concentration 
Lung spirometry
Using the MicroLab Spirometer, three attempts for Forced Maximal Expiratory capacity are made. From that, FEV1 and FVC can be
calculated. During each attempt, the subject is seated. In patients with diagnosed COPD, assessment are made post bronchodilator if
applicable..
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32. Follow-up 2 (16 weeks) - 6MWT(4)
Number Question Answers
Make sure you have the following equipment ready: HR monitor, Stopwatch, Clipboard with BORG scale and scoring form, a chair, and
portable oxygen if needed.
32.1 6MWT lap distance  10 meter normal
 10 meter f8
 30 meter ATS
32.2 Does the patient use a walking aid during the 6MWT?  Cane (Left)
 Cane (Right)
 Two canes
 Orthosis / Brace (Left)
 Orthosis / Brace (Right)
 Orthosis / Brace (Left and Right)
 Walker
 None






32.4 Stopped or paused before 6 minutes?  Yes
 No
32.4.1 If 'Stopped or paused before 6 minutes?' is equal to 'Yes' answer this
question: 
Stopped or paused? 
 Stopped before 6 minutes, not continued
 Paused and continued
32.4.2 If 'Stopped or paused before 6 minutes?' is equal to 'Yes' answer this
question: 
Provide reason for stopping or pausing during 6 minutes: 
32.5 Distance walked 
Warning shown if field's value is larger than or equal to 600: 'High value for
patients with NCD, please check' 
32.6 Other symptoms at end of exercise  angina
 dizziness
 hip, leg or calf pain
Stellenbosch University https://scholar.sun.ac.za
2020/12/04, 12:23BISHOP study
Page 60 of 76https://data.castoredc.com/print-crf/E8704677-2E2B-0B13-A42A-9…ates=0&includeHiddenCalculationFields=1&stepsOnSeparatePages=1
33. Follow-up 2 (16 weeks) - Six-Spot Step Test
Number Question Answers
33.1 SSST 
33.2 Does the patient use a walking aid during the SSST?  Cane (Left)
 Cane (Right)
 Two canes
 Orthosis / Brace (Left)
 Orthosis / Brace (Right)
 Orthosis / Brace (Left and Right)
 Walker
 None
33.3 Six Spot Step Test 0 1
Run 1 (seconds; two
decimals)
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34. Follow-up 2 (16 weeks) - Timed Up & Go Test
Number Question Answers
Patients wear their regular footwear and can use a walking aid if needed. Begin by having the patient sit back in a standard arm chair and
identify a line 3 meters. Instructions to the patient: When I say “Go,” I want you to: 1. Stand up from the chair 2. Walk to the line on the
floor at your normal pace 3. Turn 4. Walk back to the chair at your normal pace 5. Sit down again
34.1 Does the patient use a walking aid during the TUG test?  Cane (Left)
 Cane (Right)
 Two canes
 Orthosis / Brace (Left)
 Orthosis / Brace (Right)
 Orthosis / Brace (Left and Right)
 Walker
 None
34.2 Practice run  seconds (2 decimals)
34.3 Run 1  seconds (2 decimals)
34.4 Run 2  seconds (2 decimals)
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35. Follow-up 2 (16 weeks) - Questionnaire 1: IPAQ
Number Question Answers
We are interested in finding out about the kinds of physical activities that people do as part of their everyday lives. The questions are about
the time you spent being physically active in the last 7 days. They include questions about activities you do at work, as part of your house
and yard work, to get from place to place, and in your spare time for recreation, exercise or sport. Please answer each question even if you
do not consider yourself to be an active person. In answering the following questions, vigorous physical activities refer to activities that take
hard physical effort and make you breathe much harder than normal. Moderate activities refer to activities that take moderate physical
effort and make you breathe somewhat harder than normal.



































































The last question is about the time you spent sitting on weekdays while at work, at home, while doing course work and during leisure time.
This includes time spent sitting at a desk, visiting friends, reading traveling on a bus or sitting or lying down to watch television.
35.2 4. During the last 7 days, how much time in total did you usually
spend sitting on a week day? 
 [Hours.Minutes] / per day
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36. Follow-up 2 (16 weeks) - Questionnaire 2: PSQI
Number Question Answers
36.1 When have you usually gone to bed? :  (hh:mm)
36.2 How long (in minutes) has it taken you to fall asleep each night?  Minutes
36.3 What time you usually gotten up in the morning? :  (hh:mm)
36.4 How many hours of actual sleep did you get at night? :  (hh:mm)
36.5 How many hours were you in bed? :  (hh:mm)
During the past month, how often have you had trouble sleeping because you
36.6 A. Cannot get to sleep within 30 minutes  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.7 B. Wake up in the middle of the night or early morning  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.8 C. Have to get up to use the bathroom  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.9 D. Cannot breathe comfortably  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.10 E. Cough or snore loudly  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.11 F. Feel too cold  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.12 G. Feel too hot  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.13 H. Have bad dreams  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.14 I. Have pain  Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.15 J. Other reason (s), please describe, including how often you have had
trouble sleeping because of this reason (s): 
 Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.15.1 If 'J. Other reason (s), please describe, including how often you have
had trouble sleeping because of this reason (s):' is not equal to 'Not
during the past month' answer this question: 
Describe other 
36.16 During the past month, how often have you taken medicine (prescribed or
“over the counter”) to help you sleep? 
 Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
36.17 During the past month, how often have you had trouble staying awake while  Not during the past month  Less than once a week
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driving, eating meals, or engaging in social activity?  Once or twice a week  Three or more times a week
36.18 During the past month, how much of a problem has it been for you to keep
up enthusiasm to get things done? 
 Not during the past month  Less than once a week
 Once or twice a week  Three or more times a week
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37. Follow-up 2 (16 weeks) - Questionnaire 3: EQ-5D
Number Question Answers

























37.6 EQ5D - General health 
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38. Follow-up 2 (16 weeks) - Health Economics
Number Question Answers






 I don't have medical insurance
 Basic hospital plan
 Extended hospital plan with benefits
 Other











































0 1 2 3
Row Number 1 ---
Row Number 2 ---
Row Number 3 ---
Row Number 4 ---
Row Number 5 ---
Row Number 6 ---
Row Number 7 ---
Row Number 8 ---
Row Number 9 ---
Row Number 10 ---








 Reduce consumption (e.g. food)
 Sale of assets
 Borrow (e.g. from family)
 Engage in other activities than normal work to diversify income
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Productivity cost questionnaire (https://www.imta.nl)


















































you get paid. 
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days a week
do you work? 














38.6.6.1 If 'Have you
missed work


























































last 4 weeks) 














































On these days I could not do
anything
(0.00)
I was able to do just as much as I
normally do
(10.00)
Explanation Even for unpaid work, you can be bothered by physical or psychological problems. Sometimes as a result you (might) do less. For
example you have trouble caring for your children or doing voluntary work. Or you are unable to run errands and pick up groceries, or to work in







































last 4 weeks. 
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this on these
days? 
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39. Follow-up 2 (16 weeks) - 6MWT(5)
Number Question Answers
Make sure you have the following equipment ready: HR monitor, Stopwatch, Clipboard with BORG scale and scoring form, a chair, and
portable oxygen if needed.
39.1 6MWT lap distance  10 meter normal
 10 meter f8
 30 meter ATS
39.2 Does the patient use a walking aid during the 6MWT?  Cane (Left)
 Cane (Right)
 Two canes
 Orthosis / Brace (Left)
 Orthosis / Brace (Right)
 Orthosis / Brace (Left and Right)
 Walker
 None






39.4 Stopped or paused before 6 minutes?  Yes
 No
39.4.1 If 'Stopped or paused before 6 minutes?' is equal to 'Yes' answer this
question: 
Stopped or paused? 
 Stopped before 6 minutes, not continued
 Paused and continued
39.5 If 'Stopped or paused before 6 minutes?' is equal to 'Yes' answer this
question: 
Provide reason for stopping or pausing during 6 minutes: 
39.6 Distance walked 
Warning shown if field's value is larger than or equal to 600: 'High value for
patients with NCD, please check' 
39.7 Other symptoms at end of exercise  angina
 dizziness
 hip, leg or calf pain
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41. Adverse events (Treatment) - Log (S)AE
Number Question Answers
41.1 (Serious) Adverse Events 
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42. Adverse events (Assessments) - Log (S)AEs
Number Question Answers
42.1 (Serious) Adverse Events 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: Patient-centred lifestyle rehabilitation for 








Faculty of Health and Medicine 
Institute of Sports and Exercise Medicine 
Francie van Zijl drive, 7505, Cape Town 
 
CONTACT NUMBER: 021 9389801 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask 
the study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines and 
principles of the international Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for 
Research. 
 
What is this research study all about? 
This study will take place at the Bishop Lavis Clinic and Rehabilitation Centre over the 
course of one year. We anticipate that during that year, approximately 200 patients will 
be recruited to participate in this study. 
For this study we’re are looking for patients with one (or more) of the following medical 
conditions: cardiovascular disease, cancer, diabetes and/or chronic respiratory disease. 
These conditions are also referred to as “diseases of lifestyle” and often related to low 
levels of physical activity, poor nutrition, or other poor lifestyle habits like smoking 
and/or alcohol use. The Bishop Lavis Clinic provides routine medical care and additional 
education sessions to assist patients in managing their medical condition. Up to date, 
we don’t know if patients benefit, for instance in terms of mobility or quality of life, from 
these usual care services provided at the Bishop Lavis Clinic. The aim of this study is 
therefore to evaluate the routine services provided at the Bishop Lavis Clinic for the 
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You will be asked to undergo a variety of tests: walking tests, a physical examination, as 
well as answer questionnaires about your health and quality of life. You will be required 
to do this three times: at the beginning, after 8 weeks, and after 16 weeks. By repeating 
these tests, we can better understand if and how the services offered at Bishop Lavis 
benefit you as a patient or where these services may be improved. What do these tests 
look like? 
• Walking tests: The physical tests are all related to walking and your ability to move. 
We think your ability to move from A to B is very relevant for living in the Bishop 
Lavis community, as well as to your health. The following tests are included: a 6-
minute walking test, the timed up-and-go test, and the six-spot-step-test. Each of 
these tests approaches walking/mobility slightly different. If you use a walking aid, 
you can use this during these tests as well. A research assistant will conduct the 
tests and make sure the testing-environment is safe. 
o For the 6-minute walk test you will be wearing a heart-rate monitor. Over the 
course of 6 minutes you will be asked to walk as far as possible at a safe 
walking speed. We will use a quiet hallway with two pylons spaced 30 meters 
apart. You can take a rest in between if needed. At the end of the test you will 
be asked to give a score for how tired you were after walking these 6 minutes 
and we record the total distance you’ve walked. 
o For the timed up-and-go test, you will be seated in a chair with arm-rests. 
When the assessor signals “go”, you will get up out of the chair and walk a 
short 5-meter stretch as fast and safely as possible. We will record your best 
time out of three attempts. 
o For the six-spot-step-test, you will be asked to walk 5 meters. However, 
during those 5 meters you will asked to kick away small wooden blocks that 
are placed on the ground. First with your left leg, and then again with your 
right leg. An assessor will demonstrate this to you first. We will record your 
best time for each leg out of three attempts. 
• Physical examination: During the physical examination we measure your height, 
body weight, waist circumference, resting blood pressure, resting heart rate, and 
lung function. All these tests are without risk and harm (i.e. no needles etc.). For the 
lung function test, you will need to breath in and out very deeply into a small device. 
You may feel a bit out of breath following the lung function test. We expect the 
walking tests and physical examination to take about 45 minutes. 
• Questionnaires: You will be asked to answer range of questions regarding you and 
where you live, your medical condition, about your daily life and lifestyle, how you 
feel about the quality of your life, and how physically active you are. We also ask you 
to report any visits to the hospital or other medical professionals during the period 
preceding the visit with the researcher. The researcher can assist you if necessary 
or if you are uncertain on how to answer a question. All information will be treated as 
confidential. We expect that completing all questions will take about 45 minutes as 
well. 
• Once all of this is done, testing is complete! 
 
Why have you been invited to participate? 
You have been invited because you are 18 years or older and diagnosed with one or 
more of the four major non-communicable disease: cardiovascular disease, cancer, 
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chronic respiratory disease or diabetes. Your physician at the Bishop Lavis Day Clinic 
has cleared you to participate in this study. 
 
What will your responsibilities be? 
Your responsibility is to attend the three scheduled assessments with the research 
assistant over this 16 week period, to answer all questions to the best of your ability, 
and to bring forward any adverse events that happened during 16 week period. 
 
Will you benefit from taking part in this research? 
There is no direct short-term benefit for you in participating in this study. The various 
assessments may provide you with more information and knowledge regarding your 
medical condition and general health. For each completed assessment, you will receive 
a token of appreciating worth R100 to a maximal of R300 in total. 
 
Are there in risks involved in your taking part in this research? 
• Medical emergencies: Unexpected medical emergencies (collapse, fainting, 
injury during testing)  
• Testing related risks: Fall, shortness of breath 
• All of these risks will be minimized as much as possible, and treated on-site if 
they happen. All testing is done in a medical environment, and medical personnel 
will be on site to assist if necessary.  Patients with unstable and high-risk medical 
conditions are excluded from this study. 
 
If you do not agree to take part, what alternatives do you have? 
If you do not agree to take part, you will continue to receive care as usual. 
 
Who will have access to your medical records? 
 
• The information collected in this study will be treated as confidential and will be 
stored in password protected computers and back-up drives. When your 
information is exported from our data sheets for analysis, you will receive a 
number and your name will be deleted, to further protect your identity.  
• When this study is published, no identifying information will be included in the 
publication.  
• Only the testing team will have access to your information.  
• If, for some reason, this research is inspected by co-investigators, ethics 
committee members or auditors, no identifying information will be included.  
 
What will happen in the unlikely event of some form injury occurring as a direct 
result of your taking part in this research study? 
This study is covered by Stellenbosch University’s no-fault insurance policy. There is a 
qualified medical doctor part of the study team who will address injury occurring during 
testing. Injuries or adverse events are considered due to the study if they occur during 
testing and the investigator is informed of the injury during the testing session. If an 
injury occurs, you are asked to seek medical attention first and then contact Dr. Heine 
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Will you be paid to take part in this study and are there any costs involved? 
 
For each completed assessment, you will receive a token of appreciating worth R100 to 
a maximal of R300 in total. 
 
Is there any thing else that you should know or do? 
➢ We may invite you to an additional part of this research project. If this is the 
case, this will be explained to you in detail at that stage. If you decline this 
addition, this will not affect your routine medical care of your participation in this 
part of the research. 
➢ You can contact [RESEARCH ASSISTANT] if you have any further queries or 
encounter any problems. 
➢ You can contact the Health Research Ethics Committee at 021-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by 
your study doctor. 




Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled “Patient-centred lifestyle rehabilitation for non-communicable 
disease in a low-resource setting” 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
• I may be invited to an additional part of this research project to be explained 
later if applicable. I can decline participation in in this additional part without it 
affecting my routine medical care, or my participation in this section of the 
research project. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, 
as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20__. 
 
 ..............................................................   ............................................................ 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer 
them. 
• I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
• I did/did not use a interpreter.  (If a interpreter is used then the interpreter 
must sign the declaration below. 
 
 




 ..............................................................   ............................................................ 




Addendum G: Afrikaans 6MWT Instructions 
 
INSTRUKSIE TEKS (Gebruik ‘n egalige toon) 
AANVANKLIKE INSTRUKSIE:  “Die doel van hierdie toets is om so ver as moontlik te stap vir 6 minute. 
Jy gaan op en af loop in die gang. Ses minute is ’n lang tyd so jy gaan hoe vereistes stel aan jou liggaam. Jy 
sal waarskynlik moeg en uitasem word. Jy mag enige tyd stadiger loop, of heeltemal stop en rus as dit nodig 
is. Jy kan teen die muur leun om te rus maar begin weer loop sodra jy kan. Jy gaan heen en weer om die twee 
bakens loop. Ek gaan die hele tyd agter jou loop om seker te maak dat jy veilig is. Loop flink om elke baken 
en keer dan terug sonder om te huiwer. Nou gaan ek jou wys. Kyk asb na die manier waarop ek draai sonder 
om te huiwer.   
Demontreer aan die pasient deur een rondte te stap. Veral die draai om die bakens is belangrik. GAAN 
VOORT “Is jy gereed om dit te doen? Ek gaan hierdie horlosie gebruik om die rondtes te tel wat jy voltooi. 
Ek gaan hierdie knoppie druk elke keer as jy om die eerste baken gaan. Onthou die doel is om so ver as 
moontlik vir 6 minute te loop, maar moenie begin draf of hardloop nie. Jy kan begin sodra jy gereed is.   
NA DIE EERSTE MINUUT:  “Jy doen goed. Jy het 5 minute om te gaan.” 
4 MINUTE OOR: Hou aan met die goeie werk. Jy het 4 minute om te gaan. 
3 MINUTE OOR: “Wel gedaan. Jy is nou halfpad daar 
2 MINUTE OOR: Hou aan met die goeie werk. Jy het net 2 minute om te gaan. 1 MINUTE OOR: “Jy doen 
goed. Net een minuut om te gaan 
15 SEKONDES VOOR DIE EINDE: “Binne enkele oomblikke gaan ek jou vra om te stop. Wanneer ek dit 
doen wil ek he jy moet onmiddelik stop net waar jy is. Ek sal dan vir jou ’n stoel bring 
INDIEN DIE PATIENT OPHOU OM TE STAP: “Jy kan teen die muur leun as jy wil; en begin dan maar 
























DIE BORG SKAAL 
 
0  Hoegenaamd niks 
 
0,5  Baie, baie min (net-net merkbaar) 
 
1  Baie gering 
 
2  Effens (lig) 
 
3  Gematigd 
 
4  Effens straf 
 
5  Straf (swaar) 
 
6   
 
7  Baie straf 
 
8   
 
9   
 
10  Baie, baie straf 
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